Trial Outcomes & Findings for A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (NCT NCT01525550)

Last Updated: 2019-07-30

Results Overview

Investigator assessed PFS was defined as the time (in months) from the date of enrollment in study to the date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. Progression as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria was defined as: greater than or equal to (\>=) 20 percent increase in sum of longest diameter (LD) of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

106 participants

Primary outcome timeframe

Baseline until disease progression or death due to any cause (up to 1226 days)

Results posted on

2019-07-30

Participant Flow

"End of treatment" for outcome measures of ECOG-PS, EORTC QLQ-C30 and EORTC QLQ-GI NET 21 was up to "primary completion date" (PCD) only.

Participant milestones

Participant milestones
Measure	Sunitinib: Treatment Naive Cohort Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Study STARTED	61	45
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	61	45

Reasons for withdrawal

Reasons for withdrawal
Measure	Sunitinib: Treatment Naive Cohort Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Study Lost to Follow-up	8	2
Overall Study Death	19	28
Overall Study Other	0	4
Overall Study Sponsor's Decision	30	11
Overall Study Withdrawal by Subject	4	0

Baseline Characteristics

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).	Total n=106 Participants Total of all reporting groups
Age, Continuous	55.4 years STANDARD_DEVIATION 8.9 • n=5 Participants	53.5 years STANDARD_DEVIATION 9.1 • n=7 Participants	54.6 years STANDARD_DEVIATION 9.0 • n=5 Participants
Sex: Female, Male Female	31 Participants n=5 Participants	12 Participants n=7 Participants	43 Participants n=5 Participants
Sex: Female, Male Male	30 Participants n=5 Participants	33 Participants n=7 Participants	63 Participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Progression-Free Survival (PFS): Investigator Assessment	13.2 months Interval 7.4 to 16.8	13.0 months Interval 9.2 to 20.4

SECONDARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

IRR assessed PFS was defined as the time (in months) from the date of enrollment in study until the date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. Progression as per RECIST 1.0 criteria was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment	11.1 months Interval 5.5 to 16.7	9.5 months Interval 7.4 to 18.4

SECONDARY outcome

Timeframe: Baseline until first documented tumor progression (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

Investigator assessed TTP was defined as the time (in months) from the date of enrollment in study until the date of first documentation of objective tumor progression. TTP calculated as (first event date minus date of enrollment plus 1)/30.4. Progression as per RECIST 1.0 was defined as \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. The analysis was performed by Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Time to Tumor Progression (TTP): Investigator Assessment	14.8 months Interval 7.5 to 16.8	14.5 months Interval 9.2 to 20.4

SECONDARY outcome

Timeframe: Baseline until death or end of study (up to 1939 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

OS was defined as the time (in months) from date of enrollment in study to the date of death due to any cause. If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive or the end of study. The analysis was performed by Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Overall Survival (OS)	NA Months Interval 41.7 to Median and upper limit of 95% CI was not estimable due to the low number of participants who died.	37.9 Months Interval 22.9 to 56.1

SECONDARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

Investigator assessed OR in participants was defined as having a complete response (CR) or partial response (PR) according to RECIST 1.0 and sustained for at least 4 weeks. CR was defined as disappearance of all target and non-target lesions. PR was defined as \>=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Percentage of participants with investigator assessed OR were reported.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Percentage of Participants With Objective Response (OR): Investigator Assessment	21.3 percentage of participants Interval 11.9 to 33.7	28.9 percentage of participants Interval 16.4 to 44.3

SECONDARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: Analysis was performed on only those participants who had objective response as per investigator assessment.

Investigator assessed DOR was defined as the time (in months) from the date of first documented objective tumor response (CR or PR), that was subsequently confirmed, to the first documented objective tumor progression or death due to any cause, whichever occurred first. According to RECIST 1.0, CR was defined as disappearance of all target and non-target lesions. PR was defined as \>=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Progression as per RECIST version 1.0 was defined as \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=13 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=13 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Duration of Response (DOR): Investigator Assessment	19.1 months Interval 10.1 to Upper limit of 95% CI was not estimable due to the low number of participants with events.	14.7 months Interval 5.5 to 21.9

SECONDARY outcome

Timeframe: Baseline until first documented objective tumor response (up to 1226 days)

Population: Analysis was performed on only those participants who had objective response as per investigator assessment.

Investigator assessed TTR was defined as the time (in months) from date of enrollment in study until date of first documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. As per RECIST 1.0, CR was defined as disappearance of all target and non-target lesions and PR was defined as \>=30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=13 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=13 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Time to Tumor Response (TTR): Investigator Assessment	3.8 months Interval 1.0 to 11.1	3.8 months Interval 1.0 to 9.3

SECONDARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

IRR assessed OR in participants was defined as having a CR or PR according to Choi criteria and sustained for at least 4 weeks. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of \>=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on Computed tomography (CT) with no new lesions and no obvious progression of non-measurable disease. Percentage of participants with objective response were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Percentage of Participants With Objective Response (OR): Independent Radiological Review (IRR) Assessment	52.5 percentage of participants Interval 39.3 to 65.4	55.6 percentage of participants Interval 40.0 to 70.4

SECONDARY outcome

Timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)

Population: Analysis was performed on only those participants who had objective response as per IRR assessment.

IRR assessed DOR was defined as the time (in months) from the date of first documented objective tumor response (CR or PR) that was subsequently confirmed to the first documented objective tumor progression or death due to any cause, whichever occurred first. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of \>=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=32 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=25 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Duration of Response (DOR): Independent Radiological Review (IRR) Assessment	NA months Interval 17.8 to Median and 95% CI was not estimable due to the small number of participants who encountered tumor progression or death.	19.2 months Interval 15.7 to 35.9

SECONDARY outcome

Timeframe: Baseline until first documented objective tumor response (up to 1226 days)

Population: Analysis was performed on only those participants who had objective response as per IRR assessment.

IRR assessed TTR was defined as the time (in months) from date of enrollment in study until first documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of \>=10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=32 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=25 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment	1.0 months Interval 0.8 to 7.3	1.0 months Interval 0.9 to 3.7

SECONDARY outcome

Timeframe: Baseline until CgA response or death due to any cause (up to 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not.

CgA response in participants was defined as having confirmed CgA CR or CgA PR, relative to the population with an elevated baseline CgA value in the blood. CgA CR was defined as decrease from a high baseline value of CgA in the blood to one that fell within the normal range. CgA PR was defined as a decrease of greater than or equal to 50 percent from a high baseline value of CgA. Normal baseline value of CgA in blood was 39.0 ng/mL. Confirmed responses were those that persisted for at least 4 weeks after initial documentation of response. Blood levels of CgA were assessed and percentage of participants with CgA response were reported.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Percentage of Participants With Chromogranin A (CgA) Response	16.4 percentage of participants Interval 9.6 to 32.5	11.1 percentage of participants Interval 4.0 to 25.6

SECONDARY outcome

Timeframe: Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)

Population: FAS included all participants who were enrolled into the study regardless of whether participants received study drug or not. Here, "0 participants" in the "number analyzed" field signifies none of the participants were evaluable in the given group at this time point, hence data was not reported.

EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to assess the participant quality of life. First 28 questions used for evaluating 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, pain) and other single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Each question was assessed on 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much); high score represented high level of symptomatology/problem. Last 2 questions used for evaluating global health status (GHS)/quality of life. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 34	64.44 units on a scale Standard Deviation 21.430	80.00 units on a scale Standard Deviation 12.649
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 35	70.00 units on a scale Standard Deviation 23.570	78.89 units on a scale Standard Deviation 12.939
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 36	86.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	80.00 units on a scale Standard Deviation 9.428
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 37	86.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	76.67 units on a scale Standard Deviation 3.849
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 38	—	75.00 units on a scale Standard Deviation 6.383
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 39	86.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	77.78 units on a scale Standard Deviation 3.849
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 40	93.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	71.11 units on a scale Standard Deviation 10.184
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 41	—	77.78 units on a scale Standard Deviation 10.184
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: EOT	76.16 units on a scale Standard Deviation 23.454	78.00 units on a scale Standard Deviation 19.191
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 1	88.33 units on a scale Standard Deviation 20.424	85.61 units on a scale Standard Deviation 18.880
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 2	85.67 units on a scale Standard Deviation 17.089	80.56 units on a scale Standard Deviation 25.214
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 3	85.15 units on a scale Standard Deviation 18.613	80.83 units on a scale Standard Deviation 25.473
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 4	84.67 units on a scale Standard Deviation 17.444	80.26 units on a scale Standard Deviation 23.841
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 5	85.82 units on a scale Standard Deviation 19.343	82.35 units on a scale Standard Deviation 23.904
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 6	86.05 units on a scale Standard Deviation 16.639	79.57 units on a scale Standard Deviation 25.353
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 7	83.33 units on a scale Standard Deviation 21.965	81.03 units on a scale Standard Deviation 24.285
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 8	80.63 units on a scale Standard Deviation 19.049	85.33 units on a scale Standard Deviation 16.887
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 9	76.19 units on a scale Standard Deviation 22.968	80.77 units on a scale Standard Deviation 22.945
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 10	82.86 units on a scale Standard Deviation 18.737	83.33 units on a scale Standard Deviation 23.028
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 11	79.52 units on a scale Standard Deviation 22.537	86.11 units on a scale Standard Deviation 18.822
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 12	79.52 units on a scale Standard Deviation 20.246	84.85 units on a scale Standard Deviation 19.182
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 13	82.35 units on a scale Standard Deviation 19.219	84.13 units on a scale Standard Deviation 17.059
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 14	81.72 units on a scale Standard Deviation 20.346	79.82 units on a scale Standard Deviation 19.704
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 15	77.22 units on a scale Standard Deviation 22.946	77.45 units on a scale Standard Deviation 22.777
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 22	68.18 units on a scale Standard Deviation 29.302	71.21 units on a scale Standard Deviation 29.899
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 23	63.64 units on a scale Standard Deviation 30.567	71.67 units on a scale Standard Deviation 24.907
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 24	60.00 units on a scale Standard Deviation 27.442	76.67 units on a scale Standard Deviation 22.498
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 25	58.33 units on a scale Standard Deviation 30.682	77.08 units on a scale Standard Deviation 23.465
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 26	57.14 units on a scale Standard Deviation 30.211	83.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 27	58.33 units on a scale Standard Deviation 36.132	77.08 units on a scale Standard Deviation 23.465
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 29	75.00 units on a scale Standard Deviation 13.944	78.57 units on a scale Standard Deviation 24.934
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 30	90.00 units on a scale Standard Deviation 14.907	76.19 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 31	83.33 units on a scale Standard Deviation 16.667	78.57 units on a scale Standard Deviation 24.934
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 35	75.00 units on a scale Standard Deviation 35.355	72.22 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 7	80.56 units on a scale Standard Deviation 21.059	73.56 units on a scale Standard Deviation 26.075
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 16	82.10 units on a scale Standard Deviation 22.133	75.00 units on a scale Standard Deviation 24.343
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 18	78.92 units on a scale Standard Deviation 23.592	76.19 units on a scale Standard Deviation 25.499
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 19	73.61 units on a scale Standard Deviation 28.611	73.81 units on a scale Standard Deviation 25.288
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 22	75.76 units on a scale Standard Deviation 30.834	78.03 units on a scale Standard Deviation 22.445
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 37	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	77.08 units on a scale Standard Deviation 35.600
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 39	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	63.89 units on a scale Standard Deviation 48.829
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: EOT	67.17 units on a scale Standard Deviation 23.748	66.94 units on a scale Standard Deviation 27.024
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 3	89.09 units on a scale Standard Deviation 15.119	87.50 units on a scale Standard Deviation 19.882
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 8	87.39 units on a scale Standard Deviation 13.836	83.33 units on a scale Standard Deviation 21.517
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 11	86.67 units on a scale Standard Deviation 16.068	86.11 units on a scale Standard Deviation 17.492
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 16	88.27 units on a scale Standard Deviation 12.067	80.21 units on a scale Standard Deviation 24.509
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 17	89.39 units on a scale Standard Deviation 12.112	84.44 units on a scale Standard Deviation 20.380
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 19	88.89 units on a scale Standard Deviation 12.975	78.57 units on a scale Standard Deviation 24.832
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 22	86.36 units on a scale Standard Deviation 12.513	81.82 units on a scale Standard Deviation 20.350
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 24	85.00 units on a scale Standard Deviation 16.574	81.67 units on a scale Standard Deviation 19.954
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 25	81.67 units on a scale Standard Deviation 18.342	75.00 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 27	75.00 units on a scale Standard Deviation 20.412	77.08 units on a scale Standard Deviation 25.099
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 31	83.33 units on a scale Standard Deviation 23.570	73.81 units on a scale Standard Deviation 31.706
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 1	80.87 units on a scale Standard Deviation 23.734	79.46 units on a scale Standard Deviation 25.675
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 2	83.04 units on a scale Standard Deviation 20.288	82.93 units on a scale Standard Deviation 20.578
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 4	81.67 units on a scale Standard Deviation 21.626	79.82 units on a scale Standard Deviation 25.160
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 5	80.85 units on a scale Standard Deviation 21.697	79.41 units on a scale Standard Deviation 26.291
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 7	80.34 units on a scale Standard Deviation 22.579	83.91 units on a scale Standard Deviation 27.271
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 8	78.83 units on a scale Standard Deviation 21.748	80.00 units on a scale Standard Deviation 25.909
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 12	75.71 units on a scale Standard Deviation 25.030	81.82 units on a scale Standard Deviation 27.172
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 29	80.00 units on a scale Standard Deviation 18.257	71.43 units on a scale Standard Deviation 34.311
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 30	75.00 units on a scale Standard Deviation 31.914	69.05 units on a scale Standard Deviation 36.551
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 31	66.67 units on a scale Standard Deviation 47.140	71.43 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 35	66.67 units on a scale Standard Deviation 23.570	72.22 units on a scale Standard Deviation 37.515
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 42	—	41.67 units on a scale Standard Deviation 35.355
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 1	21.49 units on a scale Standard Deviation 20.374	29.42 units on a scale Standard Deviation 17.835
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 2	24.37 units on a scale Standard Deviation 17.995	29.10 units on a scale Standard Deviation 19.001
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 5	26.00 units on a scale Standard Deviation 17.069	27.61 units on a scale Standard Deviation 23.865
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 9	26.35 units on a scale Standard Deviation 20.182	22.22 units on a scale Standard Deviation 20.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 10	26.03 units on a scale Standard Deviation 19.975	24.64 units on a scale Standard Deviation 23.914
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 14	24.73 units on a scale Standard Deviation 19.183	24.56 units on a scale Standard Deviation 20.813
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 15	24.07 units on a scale Standard Deviation 20.443	24.84 units on a scale Standard Deviation 24.066
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 20	34.34 units on a scale Standard Deviation 26.036	22.22 units on a scale Standard Deviation 18.144
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 26	44.44 units on a scale Standard Deviation 27.962	22.22 units on a scale Standard Deviation 14.344
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 27	50.00 units on a scale Standard Deviation 30.429	26.39 units on a scale Standard Deviation 22.954
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 28	42.86 units on a scale Standard Deviation 28.276	30.56 units on a scale Standard Deviation 26.394
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 30	24.44 units on a scale Standard Deviation 18.257	31.75 units on a scale Standard Deviation 27.539
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 31	22.22 units on a scale Standard Deviation 29.397	31.75 units on a scale Standard Deviation 29.696
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 34	37.04 units on a scale Standard Deviation 35.717	40.74 units on a scale Standard Deviation 16.728
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 35	33.33 units on a scale Standard Deviation 47.140	35.19 units on a scale Standard Deviation 16.355
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	51.85 units on a scale Standard Deviation 33.945
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 1	6.56 units on a scale Standard Deviation 13.010	7.95 units on a scale Standard Deviation 17.420
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 4	8.00 units on a scale Standard Deviation 13.569	4.39 units on a scale Standard Deviation 9.238
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 8	7.66 units on a scale Standard Deviation 15.513	3.33 units on a scale Standard Deviation 6.804
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 10	5.71 units on a scale Standard Deviation 12.088	4.35 units on a scale Standard Deviation 9.014
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 16	4.32 units on a scale Standard Deviation 9.906	3.13 units on a scale Standard Deviation 9.065
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 28	9.52 units on a scale Standard Deviation 18.898	2.08 units on a scale Standard Deviation 5.893
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 32	5.56 units on a scale Standard Deviation 9.623	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 41	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 1	16.39 units on a scale Standard Deviation 20.067	18.18 units on a scale Standard Deviation 18.958
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 2	16.67 units on a scale Standard Deviation 18.094	19.05 units on a scale Standard Deviation 20.353
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 4	14.00 units on a scale Standard Deviation 15.922	23.25 units on a scale Standard Deviation 24.056
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 5	15.96 units on a scale Standard Deviation 16.651	18.14 units on a scale Standard Deviation 22.235
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 6	15.89 units on a scale Standard Deviation 17.041	20.43 units on a scale Standard Deviation 26.073
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 7	20.09 units on a scale Standard Deviation 21.690	22.99 units on a scale Standard Deviation 22.893
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 8	17.57 units on a scale Standard Deviation 17.099	14.67 units on a scale Standard Deviation 16.887
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 12	20.48 units on a scale Standard Deviation 22.172	16.67 units on a scale Standard Deviation 17.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 14	14.52 units on a scale Standard Deviation 17.074	21.05 units on a scale Standard Deviation 19.909
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 20	25.76 units on a scale Standard Deviation 27.247	12.82 units on a scale Standard Deviation 15.447
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 21	25.76 units on a scale Standard Deviation 29.215	16.67 units on a scale Standard Deviation 21.320
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 23	21.21 units on a scale Standard Deviation 27.979	15.00 units on a scale Standard Deviation 22.839
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 27	47.22 units on a scale Standard Deviation 35.616	20.83 units on a scale Standard Deviation 21.362
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 28	35.71 units on a scale Standard Deviation 33.923	22.92 units on a scale Standard Deviation 25.099
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 30	20.00 units on a scale Standard Deviation 21.731	19.05 units on a scale Standard Deviation 24.398
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 31	16.67 units on a scale Standard Deviation 28.868	26.19 units on a scale Standard Deviation 23.288
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 32	16.67 units on a scale Standard Deviation 28.868	27.78 units on a scale Standard Deviation 31.032
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 33	16.67 units on a scale Standard Deviation 28.868	25.00 units on a scale Standard Deviation 25.276
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 37	16.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	29.17 units on a scale Standard Deviation 28.464
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 4	6.00 units on a scale Standard Deviation 12.936	13.16 units on a scale Standard Deviation 21.280
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 7	11.11 units on a scale Standard Deviation 22.076	10.34 units on a scale Standard Deviation 20.125
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 20	6.06 units on a scale Standard Deviation 13.484	5.13 units on a scale Standard Deviation 12.518
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 21	12.12 units on a scale Standard Deviation 16.817	8.33 units on a scale Standard Deviation 15.076
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 30	6.67 units on a scale Standard Deviation 14.907	14.29 units on a scale Standard Deviation 17.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 34	11.11 units on a scale Standard Deviation 19.245	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 38	—	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: EOT	14.14 units on a scale Standard Deviation 16.730	13.33 units on a scale Standard Deviation 24.132
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 2	9.36 units on a scale Standard Deviation 16.372	19.84 units on a scale Standard Deviation 23.350
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 3	12.12 units on a scale Standard Deviation 17.408	26.67 units on a scale Standard Deviation 26.366
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 10	12.38 units on a scale Standard Deviation 18.232	21.74 units on a scale Standard Deviation 21.576
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 11	12.38 units on a scale Standard Deviation 18.232	22.22 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 12	6.67 units on a scale Standard Deviation 15.760	22.73 units on a scale Standard Deviation 27.958
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 14	8.60 units on a scale Standard Deviation 17.144	22.81 units on a scale Standard Deviation 19.413
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 18	11.76 units on a scale Standard Deviation 16.420	23.81 units on a scale Standard Deviation 24.209
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 19	13.89 units on a scale Standard Deviation 22.285	23.81 units on a scale Standard Deviation 24.209
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 20	9.09 units on a scale Standard Deviation 15.570	25.64 units on a scale Standard Deviation 24.167
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 22	15.15 units on a scale Standard Deviation 22.918	30.30 units on a scale Standard Deviation 27.707
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 23	15.15 units on a scale Standard Deviation 17.408	30.00 units on a scale Standard Deviation 33.148
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 24	10.00 units on a scale Standard Deviation 22.498	33.33 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 26	9.52 units on a scale Standard Deviation 16.265	23.81 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 27	27.78 units on a scale Standard Deviation 38.968	33.33 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 28	23.81 units on a scale Standard Deviation 25.198	25.00 units on a scale Standard Deviation 29.547
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 29	22.22 units on a scale Standard Deviation 27.217	38.10 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 30	6.67 units on a scale Standard Deviation 14.907	28.57 units on a scale Standard Deviation 29.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 31	11.11 units on a scale Standard Deviation 19.245	19.05 units on a scale Standard Deviation 26.227
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 32	22.22 units on a scale Standard Deviation 19.245	27.78 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 35	16.67 units on a scale Standard Deviation 23.570	27.78 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	26.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 38	—	33.33 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	22.22 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 42	—	16.67 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 43	—	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: EOT	16.16 units on a scale Standard Deviation 26.512	25.56 units on a scale Standard Deviation 33.543
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 2	16.96 units on a scale Standard Deviation 21.009	18.25 units on a scale Standard Deviation 22.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 4	14.00 units on a scale Standard Deviation 24.365	16.67 units on a scale Standard Deviation 26.565
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 5	10.64 units on a scale Standard Deviation 20.974	15.69 units on a scale Standard Deviation 28.704
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 6	10.85 units on a scale Standard Deviation 20.212	18.28 units on a scale Standard Deviation 30.839
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 7	14.53 units on a scale Standard Deviation 22.679	14.94 units on a scale Standard Deviation 28.986
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 8	16.22 units on a scale Standard Deviation 25.606	14.67 units on a scale Standard Deviation 25.604
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 9	14.29 units on a scale Standard Deviation 18.587	14.10 units on a scale Standard Deviation 26.954
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 10	13.33 units on a scale Standard Deviation 21.693	17.39 units on a scale Standard Deviation 28.194
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 11	15.24 units on a scale Standard Deviation 21.907	8.33 units on a scale Standard Deviation 22.522
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 12	13.33 units on a scale Standard Deviation 25.820	12.12 units on a scale Standard Deviation 24.224
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 13	13.73 units on a scale Standard Deviation 21.893	7.94 units on a scale Standard Deviation 14.548
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 14	10.75 units on a scale Standard Deviation 21.751	10.53 units on a scale Standard Deviation 19.413
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 15	13.33 units on a scale Standard Deviation 24.132	15.69 units on a scale Standard Deviation 29.149
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 16	13.58 units on a scale Standard Deviation 23.130	8.33 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 19	19.44 units on a scale Standard Deviation 33.207	9.52 units on a scale Standard Deviation 27.514
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 20	21.21 units on a scale Standard Deviation 34.230	5.13 units on a scale Standard Deviation 12.518
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 21	21.21 units on a scale Standard Deviation 34.230	16.67 units on a scale Standard Deviation 22.473
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 22	18.18 units on a scale Standard Deviation 31.140	15.15 units on a scale Standard Deviation 22.918
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 23	18.18 units on a scale Standard Deviation 31.140	10.00 units on a scale Standard Deviation 22.498
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 24	23.33 units on a scale Standard Deviation 35.312	13.33 units on a scale Standard Deviation 23.307
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 25	23.33 units on a scale Standard Deviation 41.722	8.33 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 26	38.10 units on a scale Standard Deviation 48.795	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 27	33.33 units on a scale Standard Deviation 42.164	12.50 units on a scale Standard Deviation 35.355
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 28	28.57 units on a scale Standard Deviation 40.500	16.67 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 30	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 32	11.11 units on a scale Standard Deviation 19.245	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 33	22.22 units on a scale Standard Deviation 38.490	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 35	33.33 units on a scale Standard Deviation 47.140	11.11 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 2	3.51 units on a scale Standard Deviation 10.321	13.49 units on a scale Standard Deviation 26.605
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 3	7.27 units on a scale Standard Deviation 15.303	4.17 units on a scale Standard Deviation 13.477
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 4	6.67 units on a scale Standard Deviation 15.058	5.26 units on a scale Standard Deviation 12.318
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 5	3.55 units on a scale Standard Deviation 12.499	2.94 units on a scale Standard Deviation 12.627
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 6	3.88 units on a scale Standard Deviation 10.812	2.15 units on a scale Standard Deviation 8.324
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 7	3.42 units on a scale Standard Deviation 10.245	5.75 units on a scale Standard Deviation 17.970
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 8	3.60 units on a scale Standard Deviation 13.109	4.00 units on a scale Standard Deviation 14.657
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 9	6.67 units on a scale Standard Deviation 15.760	3.85 units on a scale Standard Deviation 14.382
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 10	2.86 units on a scale Standard Deviation 9.468	5.80 units on a scale Standard Deviation 16.368
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 12	5.71 units on a scale Standard Deviation 12.746	4.55 units on a scale Standard Deviation 11.708
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 17	6.06 units on a scale Standard Deviation 13.159	2.22 units on a scale Standard Deviation 8.607
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 18	3.92 units on a scale Standard Deviation 11.070	4.76 units on a scale Standard Deviation 12.105
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 20	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 22	0.00 units on a scale Standard Deviation 0.000	12.12 units on a scale Standard Deviation 30.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 25	3.33 units on a scale Standard Deviation 10.541	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 26	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 27	5.56 units on a scale Standard Deviation 13.608	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 28	4.76 units on a scale Standard Deviation 12.599	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 29	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 31	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 33	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 34	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	13.33 units on a scale Standard Deviation 29.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 41	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 2	18.13 units on a scale Standard Deviation 26.027	17.07 units on a scale Standard Deviation 25.951
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 3	16.36 units on a scale Standard Deviation 24.740	24.17 units on a scale Standard Deviation 25.021
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 4	22.00 units on a scale Standard Deviation 27.446	15.79 units on a scale Standard Deviation 21.556
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 5	22.70 units on a scale Standard Deviation 26.105	21.57 units on a scale Standard Deviation 23.039
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 6	24.03 units on a scale Standard Deviation 29.390	22.58 units on a scale Standard Deviation 21.751
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 7	29.06 units on a scale Standard Deviation 27.762	25.29 units on a scale Standard Deviation 29.080
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 11	23.81 units on a scale Standard Deviation 25.012	23.61 units on a scale Standard Deviation 23.008
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 12	21.90 units on a scale Standard Deviation 22.785	18.18 units on a scale Standard Deviation 22.366
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 16	18.52 units on a scale Standard Deviation 25.036	20.83 units on a scale Standard Deviation 20.638
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 18	25.49 units on a scale Standard Deviation 27.712	19.05 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 19	13.89 units on a scale Standard Deviation 17.164	19.05 units on a scale Standard Deviation 21.540
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 21	33.33 units on a scale Standard Deviation 29.814	25.00 units on a scale Standard Deviation 28.868
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 22	18.18 units on a scale Standard Deviation 31.140	21.21 units on a scale Standard Deviation 26.968
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 23	24.24 units on a scale Standard Deviation 33.635	26.67 units on a scale Standard Deviation 30.631
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 25	16.67 units on a scale Standard Deviation 17.568	29.17 units on a scale Standard Deviation 27.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 26	19.05 units on a scale Standard Deviation 26.227	28.57 units on a scale Standard Deviation 29.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 29	0.00 units on a scale Standard Deviation 0.000	28.57 units on a scale Standard Deviation 29.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 30	0.00 units on a scale Standard Deviation 0.000	38.10 units on a scale Standard Deviation 23.002
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 32	22.22 units on a scale Standard Deviation 19.245	50.00 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 33	11.11 units on a scale Standard Deviation 19.245	50.00 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 34	33.33 units on a scale Standard Deviation 33.333	44.44 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 35	16.67 units on a scale Standard Deviation 23.570	38.89 units on a scale Standard Deviation 32.773
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	40.00 units on a scale Standard Deviation 43.461
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	33.33 units on a scale Standard Deviation 33.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	44.44 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: EOT	24.24 units on a scale Standard Deviation 29.194	17.78 units on a scale Standard Deviation 24.343
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 3	23.03 units on a scale Standard Deviation 30.002	30.00 units on a scale Standard Deviation 34.427
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 5	26.24 units on a scale Standard Deviation 34.005	25.49 units on a scale Standard Deviation 29.654
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 7	29.06 units on a scale Standard Deviation 31.696	27.59 units on a scale Standard Deviation 32.206
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 10	25.71 units on a scale Standard Deviation 28.105	24.64 units on a scale Standard Deviation 30.513
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 11	26.67 units on a scale Standard Deviation 27.771	23.61 units on a scale Standard Deviation 28.622
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 13	23.53 units on a scale Standard Deviation 27.864	19.05 units on a scale Standard Deviation 30.861
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 14	23.66 units on a scale Standard Deviation 28.795	17.54 units on a scale Standard Deviation 28.040
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 15	21.11 units on a scale Standard Deviation 22.289	19.61 units on a scale Standard Deviation 29.009
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 16	22.22 units on a scale Standard Deviation 22.646	18.75 units on a scale Standard Deviation 29.736
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 18	17.65 units on a scale Standard Deviation 29.149	16.67 units on a scale Standard Deviation 21.681
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 19	22.22 units on a scale Standard Deviation 32.824	14.29 units on a scale Standard Deviation 17.118
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 20	15.15 units on a scale Standard Deviation 22.918	15.38 units on a scale Standard Deviation 29.235
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 21	24.24 units on a scale Standard Deviation 33.635	16.67 units on a scale Standard Deviation 30.151
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 23	15.15 units on a scale Standard Deviation 22.918	20.00 units on a scale Standard Deviation 32.203
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 26	23.81 units on a scale Standard Deviation 31.706	28.57 units on a scale Standard Deviation 40.500
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 27	16.67 units on a scale Standard Deviation 27.889	20.83 units on a scale Standard Deviation 35.355
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 28	19.05 units on a scale Standard Deviation 26.227	20.83 units on a scale Standard Deviation 35.355
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 29	13.33 units on a scale Standard Deviation 29.814	19.05 units on a scale Standard Deviation 37.796
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 30	16.67 units on a scale Standard Deviation 33.333	19.05 units on a scale Standard Deviation 37.796
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 31	33.33 units on a scale Standard Deviation 47.140	19.05 units on a scale Standard Deviation 37.796
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 33	33.33 units on a scale Standard Deviation 33.333	22.22 units on a scale Standard Deviation 40.369
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 34	22.22 units on a scale Standard Deviation 19.245	22.22 units on a scale Standard Deviation 40.369
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 35	50.00 units on a scale Standard Deviation 23.570	22.22 units on a scale Standard Deviation 40.369
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	20.00 units on a scale Standard Deviation 44.721
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 41	—	22.22 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: EOT	30.30 units on a scale Standard Deviation 29.302	23.33 units on a scale Standard Deviation 26.479
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 22	56.06 units on a scale Standard Deviation 23.889	62.88 units on a scale Standard Deviation 27.224
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 30	52.08 units on a scale Standard Deviation 21.916	64.29 units on a scale Standard Deviation 14.996
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 7	86.24 units on a scale Standard Deviation 12.891	84.14 units on a scale Standard Deviation 15.473
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 11	84.19 units on a scale Standard Deviation 12.944	90.83 units on a scale Standard Deviation 10.552
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 12	84.38 units on a scale Standard Deviation 15.419	88.48 units on a scale Standard Deviation 11.489
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 13	87.45 units on a scale Standard Deviation 11.808	89.52 units on a scale Standard Deviation 10.016
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 23	77.73 units on a scale Standard Deviation 18.170	82.67 units on a scale Standard Deviation 14.470
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status:Cycle 1	71.31 units on a scale Standard Deviation 21.111	66.09 units on a scale Standard Deviation 20.282
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 2	69.94 units on a scale Standard Deviation 19.311	65.45 units on a scale Standard Deviation 20.880
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 3	70.30 units on a scale Standard Deviation 21.502	60.83 units on a scale Standard Deviation 26.768
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 4	70.00 units on a scale Standard Deviation 21.429	61.84 units on a scale Standard Deviation 25.010
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 5	69.15 units on a scale Standard Deviation 19.421	65.93 units on a scale Standard Deviation 24.306
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 6	68.41 units on a scale Standard Deviation 18.053	65.32 units on a scale Standard Deviation 20.310
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 7	68.38 units on a scale Standard Deviation 21.132	61.21 units on a scale Standard Deviation 24.016
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 8	70.05 units on a scale Standard Deviation 17.062	65.33 units on a scale Standard Deviation 20.649
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 9	66.90 units on a scale Standard Deviation 20.058	65.71 units on a scale Standard Deviation 20.045
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 10	68.10 units on a scale Standard Deviation 20.561	63.04 units on a scale Standard Deviation 18.434
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 11	63.81 units on a scale Standard Deviation 21.384	66.67 units on a scale Standard Deviation 19.812
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 12	65.71 units on a scale Standard Deviation 22.395	64.77 units on a scale Standard Deviation 22.848
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 13	67.89 units on a scale Standard Deviation 20.733	66.67 units on a scale Standard Deviation 19.365
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 14	68.28 units on a scale Standard Deviation 20.797	57.89 units on a scale Standard Deviation 18.937
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 15	66.67 units on a scale Standard Deviation 22.318	64.71 units on a scale Standard Deviation 21.757
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 16	64.51 units on a scale Standard Deviation 21.005	67.19 units on a scale Standard Deviation 17.339
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 17	62.50 units on a scale Standard Deviation 23.110	67.78 units on a scale Standard Deviation 15.706
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 18	58.33 units on a scale Standard Deviation 24.826	70.83 units on a scale Standard Deviation 18.125
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 19	54.86 units on a scale Standard Deviation 24.736	66.67 units on a scale Standard Deviation 20.672
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 20	55.30 units on a scale Standard Deviation 25.893	64.74 units on a scale Standard Deviation 17.398
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 21	55.30 units on a scale Standard Deviation 23.650	65.28 units on a scale Standard Deviation 18.407
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 23	56.82 units on a scale Standard Deviation 24.386	59.17 units on a scale Standard Deviation 20.953
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 24	50.00 units on a scale Standard Deviation 23.570	60.83 units on a scale Standard Deviation 19.265
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 25	51.67 units on a scale Standard Deviation 19.954	61.46 units on a scale Standard Deviation 16.022
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 26	50.00 units on a scale Standard Deviation 20.972	65.48 units on a scale Standard Deviation 13.968
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 27	41.67 units on a scale Standard Deviation 12.910	61.46 units on a scale Standard Deviation 17.216
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 28	44.05 units on a scale Standard Deviation 20.813	61.46 units on a scale Standard Deviation 16.022
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 29	56.67 units on a scale Standard Deviation 19.003	63.10 units on a scale Standard Deviation 16.567
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 31	58.33 units on a scale Standard Deviation 11.785	60.71 units on a scale Standard Deviation 20.813
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 32	61.11 units on a scale Standard Deviation 19.245	59.72 units on a scale Standard Deviation 15.290
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 33	61.11 units on a scale Standard Deviation 12.729	55.56 units on a scale Standard Deviation 22.771
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 34	58.33 units on a scale Standard Deviation 25.000	55.56 units on a scale Standard Deviation 20.861
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 35	66.67 units on a scale Standard Deviation 23.570	61.11 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 36	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	58.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 37	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	58.33 units on a scale Standard Deviation 21.517
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 38	—	58.33 units on a scale Standard Deviation 21.517
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 39	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	50.00 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 40	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	50.00 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 41	—	50.00 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 42	—	45.83 units on a scale Standard Deviation 5.893
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: Cycle 43	—	50.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global health status: EOT	60.10 units on a scale Standard Deviation 22.318	50.00 units on a scale Standard Deviation 22.210
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 1	90.38 units on a scale Standard Deviation 14.733	86.93 units on a scale Standard Deviation 12.677
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 2	89.71 units on a scale Standard Deviation 10.988	86.51 units on a scale Standard Deviation 13.929
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 3	88.73 units on a scale Standard Deviation 12.886	85.00 units on a scale Standard Deviation 17.263
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 4	89.07 units on a scale Standard Deviation 10.412	83.68 units on a scale Standard Deviation 16.958
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 5	88.23 units on a scale Standard Deviation 11.311	87.06 units on a scale Standard Deviation 17.519
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 6	87.91 units on a scale Standard Deviation 11.293	83.44 units on a scale Standard Deviation 18.924
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 8	85.23 units on a scale Standard Deviation 12.486	88.27 units on a scale Standard Deviation 11.102
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 9	84.00 units on a scale Standard Deviation 13.255	87.18 units on a scale Standard Deviation 14.474
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 10	86.67 units on a scale Standard Deviation 11.771	87.25 units on a scale Standard Deviation 15.943
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 14	86.67 units on a scale Standard Deviation 12.996	86.67 units on a scale Standard Deviation 10.423
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 15	85.33 units on a scale Standard Deviation 11.534	89.02 units on a scale Standard Deviation 11.041
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 16	83.70 units on a scale Standard Deviation 18.053	89.58 units on a scale Standard Deviation 10.319
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 17	82.42 units on a scale Standard Deviation 16.657	88.00 units on a scale Standard Deviation 9.155
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 18	82.35 units on a scale Standard Deviation 18.248	90.95 units on a scale Standard Deviation 8.516
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 19	75.00 units on a scale Standard Deviation 22.406	89.52 units on a scale Standard Deviation 9.324
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 20	74.55 units on a scale Standard Deviation 20.181	89.74 units on a scale Standard Deviation 8.439
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 21	75.15 units on a scale Standard Deviation 17.911	90.00 units on a scale Standard Deviation 7.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 22	77.58 units on a scale Standard Deviation 22.563	81.82 units on a scale Standard Deviation 24.782
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 24	72.67 units on a scale Standard Deviation 22.760	82.67 units on a scale Standard Deviation 14.807
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 25	74.67 units on a scale Standard Deviation 23.685	89.17 units on a scale Standard Deviation 10.653
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 26	66.67 units on a scale Standard Deviation 25.531	83.81 units on a scale Standard Deviation 13.801
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 27)	62.22 units on a scale Standard Deviation 27.217	85.83 units on a scale Standard Deviation 12.051
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 28	69.52 units on a scale Standard Deviation 21.381	87.50 units on a scale Standard Deviation 11.513
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 29	80.00 units on a scale Standard Deviation 10.328	83.81 units on a scale Standard Deviation 15.803
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 30	84.00 units on a scale Standard Deviation 3.651	84.76 units on a scale Standard Deviation 11.362
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 31	77.78 units on a scale Standard Deviation 10.184	85.71 units on a scale Standard Deviation 13.569
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 32	84.44 units on a scale Standard Deviation 3.849	82.22 units on a scale Standard Deviation 10.037
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 33	73.33 units on a scale Standard Deviation 6.667	83.33 units on a scale Standard Deviation 10.954
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 42	—	80.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Physical Functioning: Cycle 43	—	80.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 17	74.24 units on a scale Standard Deviation 24.520	82.22 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 16	77.16 units on a scale Standard Deviation 24.956	84.38 units on a scale Standard Deviation 15.478
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 18	75.49 units on a scale Standard Deviation 28.332	84.52 units on a scale Standard Deviation 16.621
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 19	66.67 units on a scale Standard Deviation 26.591	79.76 units on a scale Standard Deviation 20.856
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 20	69.70 units on a scale Standard Deviation 27.707	80.77 units on a scale Standard Deviation 19.059
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 21	68.18 units on a scale Standard Deviation 27.340	79.17 units on a scale Standard Deviation 23.704
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 15	76.67 units on a scale Standard Deviation 19.865	74.51 units on a scale Standard Deviation 31.797
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 16	75.93 units on a scale Standard Deviation 24.167	77.08 units on a scale Standard Deviation 25.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 17	75.00 units on a scale Standard Deviation 25.066	75.56 units on a scale Standard Deviation 25.871
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 18	76.47 units on a scale Standard Deviation 27.041	82.14 units on a scale Standard Deviation 28.090
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 19	72.22 units on a scale Standard Deviation 24.958	77.38 units on a scale Standard Deviation 26.640
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 20	75.76 units on a scale Standard Deviation 30.151	83.33 units on a scale Standard Deviation 21.517
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 21	71.21 units on a scale Standard Deviation 28.955	81.94 units on a scale Standard Deviation 26.071
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 22	69.70 units on a scale Standard Deviation 33.181	75.76 units on a scale Standard Deviation 30.151
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 23	71.21 units on a scale Standard Deviation 30.814	78.33 units on a scale Standard Deviation 31.476
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 24	63.33 units on a scale Standard Deviation 32.203	76.67 units on a scale Standard Deviation 30.631
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 25	70.00 units on a scale Standard Deviation 39.126	66.67 units on a scale Standard Deviation 34.503
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 26	61.90 units on a scale Standard Deviation 34.311	88.10 units on a scale Standard Deviation 15.853
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 27	58.33 units on a scale Standard Deviation 32.914	70.83 units on a scale Standard Deviation 33.034
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 28	73.81 units on a scale Standard Deviation 38.318	77.08 units on a scale Standard Deviation 28.084
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 32	77.78 units on a scale Standard Deviation 19.245	66.67 units on a scale Standard Deviation 36.515
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 33	66.67 units on a scale Standard Deviation 0.000	69.44 units on a scale Standard Deviation 30.581
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 34	66.67 units on a scale Standard Deviation 0.000	63.89 units on a scale Standard Deviation 37.143
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 36	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	53.33 units on a scale Standard Deviation 36.132
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 37	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	58.33 units on a scale Standard Deviation 41.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 38	—	66.67 units on a scale Standard Deviation 36.004
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 39	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	44.44 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 40	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	61.11 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 41	—	44.44 units on a scale Standard Deviation 25.459
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 43	—	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: EOT	73.74 units on a scale Standard Deviation 25.355	65.00 units on a scale Standard Deviation 29.148
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 3	26.46 units on a scale Standard Deviation 19.303	30.28 units on a scale Standard Deviation 22.644
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 4	24.00 units on a scale Standard Deviation 18.424	29.53 units on a scale Standard Deviation 24.133
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 6	25.32 units on a scale Standard Deviation 17.029	29.93 units on a scale Standard Deviation 25.526
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 7	26.78 units on a scale Standard Deviation 21.284	28.35 units on a scale Standard Deviation 24.232
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 8	27.63 units on a scale Standard Deviation 17.297	23.11 units on a scale Standard Deviation 18.681
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 11	27.94 units on a scale Standard Deviation 18.548	22.45 units on a scale Standard Deviation 20.624
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 12	26.35 units on a scale Standard Deviation 20.001	22.22 units on a scale Standard Deviation 23.256
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 13	25.16 units on a scale Standard Deviation 19.012	18.52 units on a scale Standard Deviation 15.045
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 16	27.16 units on a scale Standard Deviation 23.937	22.92 units on a scale Standard Deviation 17.902
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 17	28.28 units on a scale Standard Deviation 22.150	18.52 units on a scale Standard Deviation 18.144
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 18	26.80 units on a scale Standard Deviation 22.243	22.22 units on a scale Standard Deviation 17.433
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 19	34.26 units on a scale Standard Deviation 31.944	23.02 units on a scale Standard Deviation 20.191
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 21	34.34 units on a scale Standard Deviation 32.377	28.70 units on a scale Standard Deviation 21.429
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 22	31.31 units on a scale Standard Deviation 28.029	30.30 units on a scale Standard Deviation 27.707
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 23	39.39 units on a scale Standard Deviation 28.702	28.89 units on a scale Standard Deviation 25.229
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 24	36.67 units on a scale Standard Deviation 32.309	28.89 units on a scale Standard Deviation 26.294
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 25	40.00 units on a scale Standard Deviation 30.180	27.78 units on a scale Standard Deviation 21.414
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 29	35.19 units on a scale Standard Deviation 23.744	28.57 units on a scale Standard Deviation 21.138
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 32	18.52 units on a scale Standard Deviation 23.130	35.19 units on a scale Standard Deviation 12.989
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 33	22.22 units on a scale Standard Deviation 29.397	40.74 units on a scale Standard Deviation 20.688
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	40.00 units on a scale Standard Deviation 14.907
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	36.11 units on a scale Standard Deviation 21.033
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 38	—	44.44 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 28	59.52 units on a scale Standard Deviation 18.898	79.17 units on a scale Standard Deviation 24.801
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	59.26 units on a scale Standard Deviation 33.945
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 41	—	48.15 units on a scale Standard Deviation 23.130
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 42	—	44.44 units on a scale Standard Deviation 31.427
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: Cycle 43	—	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Fatigue: EOT	33.00 units on a scale Standard Deviation 23.812	40.56 units on a scale Standard Deviation 28.632
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 2	7.31 units on a scale Standard Deviation 12.206	7.14 units on a scale Standard Deviation 9.123
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 3	7.27 units on a scale Standard Deviation 12.735	12.08 units on a scale Standard Deviation 19.967
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 5	6.38 units on a scale Standard Deviation 12.794	8.33 units on a scale Standard Deviation 14.935
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 9	9.05 units on a scale Standard Deviation 14.766	4.49 units on a scale Standard Deviation 10.064
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 6	6.98 units on a scale Standard Deviation 12.189	6.99 units on a scale Standard Deviation 11.200
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 7	6.41 units on a scale Standard Deviation 12.458	6.90 units on a scale Standard Deviation 15.117
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 11	4.76 units on a scale Standard Deviation 10.362	4.86 units on a scale Standard Deviation 9.167
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 12	4.76 units on a scale Standard Deviation 11.835	6.06 units on a scale Standard Deviation 8.206
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 13	3.43 units on a scale Standard Deviation 8.970	2.38 units on a scale Standard Deviation 5.976
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 14	5.38 units on a scale Standard Deviation 9.988	6.14 units on a scale Standard Deviation 12.681
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 15	7.22 units on a scale Standard Deviation 12.132	5.88 units on a scale Standard Deviation 16.605
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 17	3.03 units on a scale Standard Deviation 8.351	4.44 units on a scale Standard Deviation 9.894
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 18	4.90 units on a scale Standard Deviation 11.433	1.19 units on a scale Standard Deviation 4.454
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 19	4.17 units on a scale Standard Deviation 10.360	4.76 units on a scale Standard Deviation 12.105
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 20	6.06 units on a scale Standard Deviation 15.407	1.28 units on a scale Standard Deviation 4.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 21	4.55 units on a scale Standard Deviation 15.076	6.94 units on a scale Standard Deviation 19.408
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 22	4.55 units on a scale Standard Deviation 15.076	9.09 units on a scale Standard Deviation 30.151
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 23	6.06 units on a scale Standard Deviation 15.407	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 24	6.67 units on a scale Standard Deviation 11.653	3.33 units on a scale Standard Deviation 7.027
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 25	8.33 units on a scale Standard Deviation 14.164	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 26	7.14 units on a scale Standard Deviation 8.909	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 27	11.11 units on a scale Standard Deviation 20.184	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 29	2.78 units on a scale Standard Deviation 6.804	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 30	0.00 units on a scale Standard Deviation 0.000	2.38 units on a scale Standard Deviation 6.299
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 31	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 33	22.22 units on a scale Standard Deviation 38.490	2.78 units on a scale Standard Deviation 6.804
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 34	22.22 units on a scale Standard Deviation 38.490	8.33 units on a scale Standard Deviation 13.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 35	16.67 units on a scale Standard Deviation 23.570	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 32	94.44 units on a scale Standard Deviation 9.623	77.78 units on a scale Standard Deviation 20.184
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	4.17 units on a scale Standard Deviation 8.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 38	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Nausea and Vomiting: EOT	16.16 units on a scale Standard Deviation 21.844	12.78 units on a scale Standard Deviation 20.846
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 33	88.89 units on a scale Standard Deviation 19.245	72.22 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 3	15.76 units on a scale Standard Deviation 18.542	22.50 units on a scale Standard Deviation 27.099
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 34	72.22 units on a scale Standard Deviation 34.694	69.44 units on a scale Standard Deviation 30.581
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 36	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	73.33 units on a scale Standard Deviation 19.003
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 37	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	70.83 units on a scale Standard Deviation 28.464
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 38	—	66.67 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 39	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	55.56 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 40	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	55.56 units on a scale Standard Deviation 9.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 41	—	55.56 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 42	—	66.67 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: Cycle 43	—	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Role Functioning: EOT	70.71 units on a scale Standard Deviation 26.031	65.56 units on a scale Standard Deviation 36.075
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 1	80.19 units on a scale Standard Deviation 18.644	76.23 units on a scale Standard Deviation 18.238
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 2	84.31 units on a scale Standard Deviation 17.619	77.64 units on a scale Standard Deviation 17.021
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 3	82.53 units on a scale Standard Deviation 18.792	73.96 units on a scale Standard Deviation 24.401
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 4	82.67 units on a scale Standard Deviation 16.906	77.41 units on a scale Standard Deviation 22.167
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 5	82.09 units on a scale Standard Deviation 18.632	79.66 units on a scale Standard Deviation 21.141
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 6	82.17 units on a scale Standard Deviation 17.871	73.92 units on a scale Standard Deviation 24.696
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 8	80.63 units on a scale Standard Deviation 21.877	76.00 units on a scale Standard Deviation 18.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 9	80.24 units on a scale Standard Deviation 19.812	76.92 units on a scale Standard Deviation 18.304
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 10	81.27 units on a scale Standard Deviation 19.818	76.45 units on a scale Standard Deviation 21.998
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 11	79.76 units on a scale Standard Deviation 19.311	75.46 units on a scale Standard Deviation 20.587
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 12	78.10 units on a scale Standard Deviation 23.052	75.76 units on a scale Standard Deviation 22.700
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 13	77.45 units on a scale Standard Deviation 22.429	77.38 units on a scale Standard Deviation 19.211
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 14	78.49 units on a scale Standard Deviation 20.387	75.00 units on a scale Standard Deviation 24.375
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 15	80.00 units on a scale Standard Deviation 21.173	74.51 units on a scale Standard Deviation 23.839
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 17	79.92 units on a scale Standard Deviation 23.522	79.44 units on a scale Standard Deviation 19.382
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 20	71.21 units on a scale Standard Deviation 29.666	78.85 units on a scale Standard Deviation 25.823
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 21	76.52 units on a scale Standard Deviation 28.824	75.00 units on a scale Standard Deviation 25.624
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 23	74.24 units on a scale Standard Deviation 30.834	75.00 units on a scale Standard Deviation 27.778
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 24	71.67 units on a scale Standard Deviation 28.921	76.67 units on a scale Standard Deviation 22.153
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 25	65.83 units on a scale Standard Deviation 33.206	66.67 units on a scale Standard Deviation 29.881
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 26	71.43 units on a scale Standard Deviation 34.979	77.38 units on a scale Standard Deviation 17.156
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 27	56.94 units on a scale Standard Deviation 32.667	68.75 units on a scale Standard Deviation 29.124
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 28	65.48 units on a scale Standard Deviation 34.166	68.75 units on a scale Standard Deviation 29.463
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 29	68.33 units on a scale Standard Deviation 29.698	71.43 units on a scale Standard Deviation 31.127
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 30	72.92 units on a scale Standard Deviation 29.950	70.24 units on a scale Standard Deviation 31.497
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 31	45.83 units on a scale Standard Deviation 17.678	72.62 units on a scale Standard Deviation 26.227
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 32	69.44 units on a scale Standard Deviation 29.266	69.44 units on a scale Standard Deviation 33.610
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 33	77.78 units on a scale Standard Deviation 19.245	70.83 units on a scale Standard Deviation 27.764
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 34	66.67 units on a scale Standard Deviation 33.333	66.67 units on a scale Standard Deviation 34.561
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 35	83.33 units on a scale Standard Deviation 23.570	68.06 units on a scale Standard Deviation 33.918
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 36	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	71.67 units on a scale Standard Deviation 31.513
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 38	—	70.83 units on a scale Standard Deviation 42.219
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 40	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	66.67 units on a scale Standard Deviation 38.188
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 41	—	58.33 units on a scale Standard Deviation 41.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 42	—	54.17 units on a scale Standard Deviation 64.818
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Emotional Functioning: Cycle 43	—	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 1	90.16 units on a scale Standard Deviation 15.329	88.76 units on a scale Standard Deviation 15.310
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 2	88.89 units on a scale Standard Deviation 15.537	89.43 units on a scale Standard Deviation 13.310
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 4	89.67 units on a scale Standard Deviation 12.993	87.72 units on a scale Standard Deviation 15.346
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 5	88.65 units on a scale Standard Deviation 15.583	85.29 units on a scale Standard Deviation 22.385
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 6	89.53 units on a scale Standard Deviation 15.006	82.80 units on a scale Standard Deviation 25.993
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 7	89.74 units on a scale Standard Deviation 14.618	85.06 units on a scale Standard Deviation 20.091
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 9	88.10 units on a scale Standard Deviation 16.455	85.26 units on a scale Standard Deviation 20.181
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 10	88.10 units on a scale Standard Deviation 13.750	83.33 units on a scale Standard Deviation 21.320
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 12	86.67 units on a scale Standard Deviation 13.886	86.36 units on a scale Standard Deviation 18.993
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 13	87.25 units on a scale Standard Deviation 15.922	85.71 units on a scale Standard Deviation 19.211
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 14	88.71 units on a scale Standard Deviation 13.185	77.19 units on a scale Standard Deviation 22.368
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 15	88.33 units on a scale Standard Deviation 12.495	80.39 units on a scale Standard Deviation 27.154
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 18	88.24 units on a scale Standard Deviation 14.148	79.76 units on a scale Standard Deviation 24.615
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 20	90.91 units on a scale Standard Deviation 11.459	82.05 units on a scale Standard Deviation 24.964
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 21	89.39 units on a scale Standard Deviation 11.237	76.39 units on a scale Standard Deviation 26.071
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 23	84.85 units on a scale Standard Deviation 11.677	76.67 units on a scale Standard Deviation 27.442
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 26	85.71 units on a scale Standard Deviation 20.250	85.71 units on a scale Standard Deviation 17.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 28	76.19 units on a scale Standard Deviation 18.898	72.92 units on a scale Standard Deviation 29.463
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 29	76.67 units on a scale Standard Deviation 14.907	78.57 units on a scale Standard Deviation 26.726
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 30	75.00 units on a scale Standard Deviation 16.667	76.19 units on a scale Standard Deviation 31.706
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 32	83.33 units on a scale Standard Deviation 16.667	69.44 units on a scale Standard Deviation 32.347
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 33	88.89 units on a scale Standard Deviation 19.245	69.44 units on a scale Standard Deviation 26.701
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 34	77.78 units on a scale Standard Deviation 9.623	66.67 units on a scale Standard Deviation 34.960
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 35	100.00 units on a scale Standard Deviation 0.000	75.00 units on a scale Standard Deviation 27.386
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 36	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	73.33 units on a scale Standard Deviation 34.561
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 37	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	75.00 units on a scale Standard Deviation 39.675
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 38	—	70.83 units on a scale Standard Deviation 47.871
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 39	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	72.22 units on a scale Standard Deviation 34.694
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 40	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	61.11 units on a scale Standard Deviation 34.694
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 15	8.89 units on a scale Standard Deviation 14.993	9.80 units on a scale Standard Deviation 15.656
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 41	—	61.11 units on a scale Standard Deviation 41.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 42	—	50.00 units on a scale Standard Deviation 70.711
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: Cycle 43	—	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Cognitive Functioning: EOT	83.33 units on a scale Standard Deviation 17.180	78.33 units on a scale Standard Deviation 23.631
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 3	79.09 units on a scale Standard Deviation 23.399	77.08 units on a scale Standard Deviation 26.335
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 6	80.23 units on a scale Standard Deviation 28.232	77.42 units on a scale Standard Deviation 28.398
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 9	77.62 units on a scale Standard Deviation 24.234	82.05 units on a scale Standard Deviation 23.534
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 10	81.43 units on a scale Standard Deviation 20.119	76.81 units on a scale Standard Deviation 26.939
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 11	76.19 units on a scale Standard Deviation 23.321	81.25 units on a scale Standard Deviation 26.151
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 13	77.94 units on a scale Standard Deviation 25.859	84.92 units on a scale Standard Deviation 21.670
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Social Functioning: Cycle 14	81.18 units on a scale Standard Deviation 20.968	79.82 units on a scale Standard Deviation 29.700
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 19	0.00 units on a scale Standard Deviation 0.000	9.52 units on a scale Standard Deviation 20.375
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 21	0.00 units on a scale Standard Deviation 0.000	2.78 units on a scale Standard Deviation 9.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 23	0.00 units on a scale Standard Deviation 0.000	3.33 units on a scale Standard Deviation 10.541
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 24	0.00 units on a scale Standard Deviation 0.000	6.67 units on a scale Standard Deviation 14.055
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 9	20.48 units on a scale Standard Deviation 19.838	19.87 units on a scale Standard Deviation 19.447
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 30	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 10	19.52 units on a scale Standard Deviation 22.682	18.84 units on a scale Standard Deviation 22.079
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 11	19.05 units on a scale Standard Deviation 19.446	13.89 units on a scale Standard Deviation 18.169
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 32	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 13	17.16 units on a scale Standard Deviation 15.616	15.87 units on a scale Standard Deviation 20.053
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 15	15.00 units on a scale Standard Deviation 23.305	21.57 units on a scale Standard Deviation 24.127
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 35	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 16	17.28 units on a scale Standard Deviation 21.917	15.63 units on a scale Standard Deviation 14.232
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 17	18.94 units on a scale Standard Deviation 23.171	15.56 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 18	16.67 units on a scale Standard Deviation 22.048	10.71 units on a scale Standard Deviation 16.803
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 19	26.39 units on a scale Standard Deviation 27.941	13.10 units on a scale Standard Deviation 16.249
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 22	18.18 units on a scale Standard Deviation 26.304	21.21 units on a scale Standard Deviation 21.201
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 24	28.33 units on a scale Standard Deviation 26.117	20.00 units on a scale Standard Deviation 24.595
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 25	26.67 units on a scale Standard Deviation 30.631	16.67 units on a scale Standard Deviation 19.920
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 26	38.10 units on a scale Standard Deviation 40.500	16.67 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 29	19.44 units on a scale Standard Deviation 19.484	23.81 units on a scale Standard Deviation 26.972
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 34	22.22 units on a scale Standard Deviation 38.490	27.78 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 35	25.00 units on a scale Standard Deviation 35.355	22.22 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	20.00 units on a scale Standard Deviation 13.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 38	—	29.17 units on a scale Standard Deviation 28.464
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	38.89 units on a scale Standard Deviation 25.459
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	44.44 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 41	—	55.56 units on a scale Standard Deviation 41.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 42	—	33.33 units on a scale Standard Deviation 47.140
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: Cycle 43	—	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Pain: EOT	23.74 units on a scale Standard Deviation 25.695	33.89 units on a scale Standard Deviation 32.009
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 1	5.00 units on a scale Standard Deviation 12.003	7.58 units on a scale Standard Deviation 15.854
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 2	7.02 units on a scale Standard Deviation 15.088	8.73 units on a scale Standard Deviation 18.123
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 3	6.06 units on a scale Standard Deviation 12.975	9.17 units on a scale Standard Deviation 21.334
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 5	5.67 units on a scale Standard Deviation 14.445	10.78 units on a scale Standard Deviation 22.801
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 6	6.98 units on a scale Standard Deviation 15.530	10.75 units on a scale Standard Deviation 24.925
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 8	15.32 units on a scale Standard Deviation 21.652	6.67 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 9	9.52 units on a scale Standard Deviation 20.725	5.13 units on a scale Standard Deviation 12.265
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 10	9.52 units on a scale Standard Deviation 15.278	10.14 units on a scale Standard Deviation 21.165
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 11	5.71 units on a scale Standard Deviation 12.746	9.72 units on a scale Standard Deviation 15.477
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 12	8.57 units on a scale Standard Deviation 14.781	6.06 units on a scale Standard Deviation 13.159
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 13	10.78 units on a scale Standard Deviation 15.829	12.70 units on a scale Standard Deviation 19.653
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 14	9.68 units on a scale Standard Deviation 15.380	8.77 units on a scale Standard Deviation 15.080
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 16	6.17 units on a scale Standard Deviation 13.195	6.25 units on a scale Standard Deviation 13.437
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 17	10.61 units on a scale Standard Deviation 15.891	6.67 units on a scale Standard Deviation 13.801
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 18	7.84 units on a scale Standard Deviation 14.575	4.76 units on a scale Standard Deviation 12.105
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 19	13.89 units on a scale Standard Deviation 17.164	4.76 units on a scale Standard Deviation 12.105
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 22	9.09 units on a scale Standard Deviation 15.570	9.09 units on a scale Standard Deviation 15.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 23	6.06 units on a scale Standard Deviation 13.484	13.33 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 24	6.67 units on a scale Standard Deviation 14.055	13.33 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 25	13.33 units on a scale Standard Deviation 23.307	8.33 units on a scale Standard Deviation 15.430
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 26	9.52 units on a scale Standard Deviation 16.265	9.52 units on a scale Standard Deviation 16.265
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 27	11.11 units on a scale Standard Deviation 27.217	8.33 units on a scale Standard Deviation 15.430
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 28	19.05 units on a scale Standard Deviation 17.817	12.50 units on a scale Standard Deviation 17.252
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 29	11.11 units on a scale Standard Deviation 27.217	19.05 units on a scale Standard Deviation 17.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 31	0.00 units on a scale Standard Deviation 0.000	9.52 units on a scale Standard Deviation 16.265
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 32	11.11 units on a scale Standard Deviation 19.245	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 33	22.22 units on a scale Standard Deviation 38.490	11.11 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 35	16.67 units on a scale Standard Deviation 23.570	11.11 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	26.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 38	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: EOT	10.10 units on a scale Standard Deviation 19.516	3.33 units on a scale Standard Deviation 10.171
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 1	14.21 units on a scale Standard Deviation 22.327	11.63 units on a scale Standard Deviation 17.644
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 41	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 42	—	16.67 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Dyspnoea: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 1	13.11 units on a scale Standard Deviation 20.438	25.76 units on a scale Standard Deviation 27.715
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 4	11.33 units on a scale Standard Deviation 19.760	24.56 units on a scale Standard Deviation 27.601
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 5	9.22 units on a scale Standard Deviation 19.289	17.65 units on a scale Standard Deviation 26.253
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 6	10.85 units on a scale Standard Deviation 18.857	20.43 units on a scale Standard Deviation 26.774
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 7	9.40 units on a scale Standard Deviation 18.651	21.84 units on a scale Standard Deviation 28.558
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 8	10.81 units on a scale Standard Deviation 20.867	21.33 units on a scale Standard Deviation 21.257
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 9	11.43 units on a scale Standard Deviation 19.708	20.51 units on a scale Standard Deviation 23.242
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 13	9.80 units on a scale Standard Deviation 15.417	23.81 units on a scale Standard Deviation 21.455
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 15	9.20 units on a scale Standard Deviation 17.586	25.49 units on a scale Standard Deviation 25.082
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 16	9.88 units on a scale Standard Deviation 20.286	25.00 units on a scale Standard Deviation 28.545
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 17	6.06 units on a scale Standard Deviation 16.703	22.22 units on a scale Standard Deviation 24.125
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 21	18.18 units on a scale Standard Deviation 22.918	30.56 units on a scale Standard Deviation 26.432
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 25	23.33 units on a scale Standard Deviation 27.442	29.17 units on a scale Standard Deviation 27.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 33	22.22 units on a scale Standard Deviation 19.245	22.22 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 34	22.22 units on a scale Standard Deviation 38.490	27.78 units on a scale Standard Deviation 25.092
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 8	26.13 units on a scale Standard Deviation 27.369	20.00 units on a scale Standard Deviation 28.868
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	33.33 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Insomnia: Cycle 41	—	22.22 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 9	30.48 units on a scale Standard Deviation 30.648	29.49 units on a scale Standard Deviation 33.102
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 10	24.76 units on a scale Standard Deviation 26.000	27.54 units on a scale Standard Deviation 29.563
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 1	12.57 units on a scale Standard Deviation 21.225	15.91 units on a scale Standard Deviation 23.282
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 3	13.94 units on a scale Standard Deviation 18.912	20.83 units on a scale Standard Deviation 28.929
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 13	21.57 units on a scale Standard Deviation 21.528	19.05 units on a scale Standard Deviation 27.021
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 14	23.66 units on a scale Standard Deviation 23.084	19.30 units on a scale Standard Deviation 20.233
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 15	21.11 units on a scale Standard Deviation 23.947	25.49 units on a scale Standard Deviation 22.140
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 17	21.21 units on a scale Standard Deviation 19.370	15.56 units on a scale Standard Deviation 24.774
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 20	27.27 units on a scale Standard Deviation 20.101	23.08 units on a scale Standard Deviation 25.036
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 17	10.61 units on a scale Standard Deviation 23.874	6.67 units on a scale Standard Deviation 18.687
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 18	17.65 units on a scale Standard Deviation 29.149	9.52 units on a scale Standard Deviation 20.375
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 29	11.11 units on a scale Standard Deviation 27.217	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 31	0.00 units on a scale Standard Deviation 0.000	9.52 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 34	33.33 units on a scale Standard Deviation 57.735	27.78 units on a scale Standard Deviation 32.773
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 38	—	16.67 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 41	—	22.22 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 42	—	16.67 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Appetite Loss: EOT	27.27 units on a scale Standard Deviation 34.816	26.67 units on a scale Standard Deviation 32.044
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 1	7.10 units on a scale Standard Deviation 17.336	9.09 units on a scale Standard Deviation 18.135
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 11	3.81 units on a scale Standard Deviation 13.459	2.78 units on a scale Standard Deviation 9.411
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 13	2.94 units on a scale Standard Deviation 9.597	1.59 units on a scale Standard Deviation 7.274
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 14	1.08 units on a scale Standard Deviation 5.987	3.51 units on a scale Standard Deviation 10.510
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 15	2.22 units on a scale Standard Deviation 8.457	3.92 units on a scale Standard Deviation 16.169
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Constipation: Cycle 16	2.47 units on a scale Standard Deviation 8.896	6.25 units on a scale Standard Deviation 13.437
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 24	23.33 units on a scale Standard Deviation 22.498	23.33 units on a scale Standard Deviation 31.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 27	22.22 units on a scale Standard Deviation 17.213	37.50 units on a scale Standard Deviation 33.034
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 28	14.29 units on a scale Standard Deviation 17.817	29.17 units on a scale Standard Deviation 27.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 31	0.00 units on a scale Standard Deviation 0.000	33.33 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	25.00 units on a scale Standard Deviation 31.914
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 38	—	41.67 units on a scale Standard Deviation 31.914
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 41	—	44.44 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 42	—	50.00 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Diarrhoea: Cycle 43	—	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 1	25.68 units on a scale Standard Deviation 35.691	31.01 units on a scale Standard Deviation 33.646
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 2	23.39 units on a scale Standard Deviation 28.843	21.95 units on a scale Standard Deviation 26.468
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 4	24.00 units on a scale Standard Deviation 30.147	28.95 units on a scale Standard Deviation 27.037
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 6	27.13 units on a scale Standard Deviation 35.078	26.88 units on a scale Standard Deviation 31.528
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 8	30.63 units on a scale Standard Deviation 32.753	25.33 units on a scale Standard Deviation 29.313
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 9	22.86 units on a scale Standard Deviation 28.892	20.51 units on a scale Standard Deviation 29.929
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 12	26.67 units on a scale Standard Deviation 30.033	19.70 units on a scale Standard Deviation 26.546
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 17	19.70 units on a scale Standard Deviation 24.471	15.56 units on a scale Standard Deviation 27.794
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 22	18.18 units on a scale Standard Deviation 27.340	15.15 units on a scale Standard Deviation 22.918
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 24	20.00 units on a scale Standard Deviation 28.109	16.67 units on a scale Standard Deviation 32.394
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 25	16.67 units on a scale Standard Deviation 28.328	29.17 units on a scale Standard Deviation 37.533
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 32	22.22 units on a scale Standard Deviation 38.490	22.22 units on a scale Standard Deviation 40.369
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 37	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 38	—	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Financial Difficulties: Cycle 40	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245

SECONDARY outcome

EORTC QLQ-GI-NET 21 was a 21-item questionnaire. These 21 questions assesses endocrine symptoms, gastrointestinal (G.I.) symptoms, treatment related symptoms, social functioning, disease related worries, muscle/bone pain, sexual function, information/communication function and body image. Each item was answered on a 4-point scale: 1 =not at all, 2 =a little, 3 =quite a bit, 4 =very much; where higher scores indicated more severe symptoms/problems. Scores averaged, transformed to 0-100 scale; higher score=more severe symptoms.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 30	20.37 units on a scale Standard Deviation 3.208	15.87 units on a scale Standard Deviation 14.138
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 32	16.67 units on a scale Standard Deviation 5.556	20.37 units on a scale Standard Deviation 7.590
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 42	—	27.78 units on a scale Standard Deviation 7.857
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 34	27.78 units on a scale Standard Deviation 9.623	20.37 units on a scale Standard Deviation 12.989
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 3	14.75 units on a scale Standard Deviation 20.066	11.67 units on a scale Standard Deviation 14.443
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 4	12.67 units on a scale Standard Deviation 15.227	12.31 units on a scale Standard Deviation 14.531
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 6	13.18 units on a scale Standard Deviation 16.490	9.32 units on a scale Standard Deviation 13.788
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 8	13.81 units on a scale Standard Deviation 18.408	10.67 units on a scale Standard Deviation 14.515
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 9	10.16 units on a scale Standard Deviation 14.851	11.11 units on a scale Standard Deviation 14.741
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 10	10.16 units on a scale Standard Deviation 13.304	14.01 units on a scale Standard Deviation 18.416
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 11	13.02 units on a scale Standard Deviation 16.934	13.43 units on a scale Standard Deviation 19.653
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 12	12.06 units on a scale Standard Deviation 16.693	11.62 units on a scale Standard Deviation 17.644
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 14	12.19 units on a scale Standard Deviation 16.815	14.62 units on a scale Standard Deviation 18.538
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 17	12.12 units on a scale Standard Deviation 18.753	8.89 units on a scale Standard Deviation 10.457
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 18	11.11 units on a scale Standard Deviation 18.840	11.90 units on a scale Standard Deviation 14.756
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 19	14.81 units on a scale Standard Deviation 21.364	6.35 units on a scale Standard Deviation 11.293
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 23	18.18 units on a scale Standard Deviation 15.131	13.33 units on a scale Standard Deviation 16.397
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 25	16.67 units on a scale Standard Deviation 23.570	8.33 units on a scale Standard Deviation 12.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 26	22.22 units on a scale Standard Deviation 27.962	7.94 units on a scale Standard Deviation 13.929
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 27	22.22 units on a scale Standard Deviation 28.109	9.72 units on a scale Standard Deviation 12.511
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 29	12.96 units on a scale Standard Deviation 12.989	11.11 units on a scale Standard Deviation 12.830
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 30	8.89 units on a scale Standard Deviation 9.296	14.29 units on a scale Standard Deviation 13.929
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 31	14.81 units on a scale Standard Deviation 6.415	12.70 units on a scale Standard Deviation 11.878
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 32	7.41 units on a scale Standard Deviation 12.830	14.81 units on a scale Standard Deviation 13.456
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 33	11.11 units on a scale Standard Deviation 0.000	16.67 units on a scale Standard Deviation 11.653
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 34	18.52 units on a scale Standard Deviation 6.415	20.37 units on a scale Standard Deviation 23.744
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 35	22.22 units on a scale Standard Deviation 0.000	16.67 units on a scale Standard Deviation 16.851
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 36	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	17.78 units on a scale Standard Deviation 18.592
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 37	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	5.56 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 38	—	8.33 units on a scale Standard Deviation 10.638
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 39	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 40	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 41	—	11.11 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: EOT	13.80 units on a scale Standard Deviation 15.474	11.11 units on a scale Standard Deviation 16.534
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 1	15.41 units on a scale Standard Deviation 14.633	15.30 units on a scale Standard Deviation 13.301
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 2	17.66 units on a scale Standard Deviation 14.057	17.72 units on a scale Standard Deviation 13.631
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 3	20.24 units on a scale Standard Deviation 17.543	19.50 units on a scale Standard Deviation 16.702
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 4	19.47 units on a scale Standard Deviation 16.814	19.30 units on a scale Standard Deviation 17.315
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 5	15.18 units on a scale Standard Deviation 13.528	21.01 units on a scale Standard Deviation 17.569
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 6	18.76 units on a scale Standard Deviation 16.982	21.51 units on a scale Standard Deviation 20.273
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 7	18.63 units on a scale Standard Deviation 19.114	20.23 units on a scale Standard Deviation 18.728
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 8	20.72 units on a scale Standard Deviation 19.359	19.47 units on a scale Standard Deviation 15.743
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 9	18.86 units on a scale Standard Deviation 18.040	19.49 units on a scale Standard Deviation 17.681
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 10	18.38 units on a scale Standard Deviation 17.916	19.78 units on a scale Standard Deviation 18.315
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 11	18.86 units on a scale Standard Deviation 15.295	16.94 units on a scale Standard Deviation 17.360
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 12	18.86 units on a scale Standard Deviation 18.040	18.79 units on a scale Standard Deviation 20.741
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 13	18.04 units on a scale Standard Deviation 17.641	14.60 units on a scale Standard Deviation 13.600
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 14	18.06 units on a scale Standard Deviation 18.871	16.49 units on a scale Standard Deviation 13.943
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 15	19.56 units on a scale Standard Deviation 17.934	22.35 units on a scale Standard Deviation 22.966
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 16	17.53 units on a scale Standard Deviation 17.458	17.50 units on a scale Standard Deviation 14.782
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 17	18.18 units on a scale Standard Deviation 19.099	13.78 units on a scale Standard Deviation 12.206
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 19	23.89 units on a scale Standard Deviation 21.360	20.48 units on a scale Standard Deviation 20.500
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 21	29.09 units on a scale Standard Deviation 22.759	17.22 units on a scale Standard Deviation 16.927
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 22	23.03 units on a scale Standard Deviation 21.574	18.18 units on a scale Standard Deviation 18.641
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 23	27.27 units on a scale Standard Deviation 26.408	20.00 units on a scale Standard Deviation 18.856
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 24	26.00 units on a scale Standard Deviation 20.476	21.33 units on a scale Standard Deviation 18.539
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 25	24.67 units on a scale Standard Deviation 19.386	23.33 units on a scale Standard Deviation 17.090
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 26	30.48 units on a scale Standard Deviation 17.152	20.95 units on a scale Standard Deviation 15.601
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 29	22.22 units on a scale Standard Deviation 5.443	28.57 units on a scale Standard Deviation 17.090
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 30	18.67 units on a scale Standard Deviation 15.202	21.90 units on a scale Standard Deviation 17.518
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 32	22.22 units on a scale Standard Deviation 27.756	27.78 units on a scale Standard Deviation 19.052
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 33	26.67 units on a scale Standard Deviation 35.277	23.33 units on a scale Standard Deviation 17.256
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 34	20.00 units on a scale Standard Deviation 29.059	28.89 units on a scale Standard Deviation 15.587
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 35	23.33 units on a scale Standard Deviation 32.998	20.00 units on a scale Standard Deviation 15.202
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	17.33 units on a scale Standard Deviation 15.348
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	21.67 units on a scale Standard Deviation 13.744
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms:EOT	23.23 units on a scale Standard Deviation 18.568	18.85 units on a scale Standard Deviation 19.766
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 2	14.48 units on a scale Standard Deviation 11.686	16.20 units on a scale Standard Deviation 14.141
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 3	15.42 units on a scale Standard Deviation 12.280	17.09 units on a scale Standard Deviation 18.574
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 6	15.45 units on a scale Standard Deviation 13.293	15.00 units on a scale Standard Deviation 17.577
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 10	15.99 units on a scale Standard Deviation 15.760	16.91 units on a scale Standard Deviation 17.446
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 16	13.78 units on a scale Standard Deviation 13.714	10.74 units on a scale Standard Deviation 14.467
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 18	17.71 units on a scale Standard Deviation 16.999	10.71 units on a scale Standard Deviation 11.828
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 19	20.00 units on a scale Standard Deviation 17.013	12.30 units on a scale Standard Deviation 13.287
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 21	18.18 units on a scale Standard Deviation 18.608	14.81 units on a scale Standard Deviation 14.279
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 26	26.19 units on a scale Standard Deviation 21.448	12.70 units on a scale Standard Deviation 11.437
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 27	37.96 units on a scale Standard Deviation 16.636	19.44 units on a scale Standard Deviation 18.306
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 28	35.56 units on a scale Standard Deviation 21.009	17.36 units on a scale Standard Deviation 15.555
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 43	—	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: EOT	24.33 units on a scale Standard Deviation 20.542	20.78 units on a scale Standard Deviation 24.969
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 6	25.71 units on a scale Standard Deviation 21.138	28.32 units on a scale Standard Deviation 23.101
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 8	30.63 units on a scale Standard Deviation 20.015	27.11 units on a scale Standard Deviation 20.051
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 12	28.25 units on a scale Standard Deviation 24.454	23.74 units on a scale Standard Deviation 22.562
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 15	28.52 units on a scale Standard Deviation 20.149	28.76 units on a scale Standard Deviation 28.070
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 16	27.16 units on a scale Standard Deviation 20.286	27.78 units on a scale Standard Deviation 23.307
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 24	38.89 units on a scale Standard Deviation 28.328	24.44 units on a scale Standard Deviation 24.456
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 25	35.56 units on a scale Standard Deviation 27.116	31.94 units on a scale Standard Deviation 26.184
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 26	46.03 units on a scale Standard Deviation 28.276	22.22 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 28	46.03 units on a scale Standard Deviation 33.597	31.94 units on a scale Standard Deviation 29.360
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 29	35.19 units on a scale Standard Deviation 25.740	28.57 units on a scale Standard Deviation 27.857
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 35	38.89 units on a scale Standard Deviation 23.570	33.33 units on a scale Standard Deviation 24.343
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 36	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	31.11 units on a scale Standard Deviation 27.666
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 39	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	51.85 units on a scale Standard Deviation 44.905
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 42	—	38.89 units on a scale Standard Deviation 39.284
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: EOT	39.73 units on a scale Standard Deviation 25.914	41.38 units on a scale Standard Deviation 26.874
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 3	36.46 units on a scale Standard Deviation 23.074	34.58 units on a scale Standard Deviation 23.853
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 6	36.43 units on a scale Standard Deviation 25.148	34.05 units on a scale Standard Deviation 25.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 9	35.71 units on a scale Standard Deviation 31.116	32.05 units on a scale Standard Deviation 22.072
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 10	37.30 units on a scale Standard Deviation 26.458	28.02 units on a scale Standard Deviation 26.563
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 11	35.87 units on a scale Standard Deviation 25.292	27.78 units on a scale Standard Deviation 22.700
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 17	29.80 units on a scale Standard Deviation 22.059	34.07 units on a scale Standard Deviation 27.043
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 18	30.07 units on a scale Standard Deviation 28.805	32.14 units on a scale Standard Deviation 27.232
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 19	37.50 units on a scale Standard Deviation 29.504	31.75 units on a scale Standard Deviation 28.862
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 20	40.40 units on a scale Standard Deviation 32.687	29.91 units on a scale Standard Deviation 31.877
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 22	33.33 units on a scale Standard Deviation 31.032	30.30 units on a scale Standard Deviation 34.816
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 27	52.78 units on a scale Standard Deviation 40.023	34.72 units on a scale Standard Deviation 28.133
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 31	48.15 units on a scale Standard Deviation 46.259	36.51 units on a scale Standard Deviation 32.530
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 32	25.93 units on a scale Standard Deviation 23.130	37.04 units on a scale Standard Deviation 38.276
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 33	51.85 units on a scale Standard Deviation 42.066	35.19 units on a scale Standard Deviation 36.118
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 35	16.67 units on a scale Standard Deviation 23.570	35.19 units on a scale Standard Deviation 34.006
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	31.11 units on a scale Standard Deviation 36.345
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 6	18.60 units on a scale Standard Deviation 20.959	20.43 units on a scale Standard Deviation 23.847
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 7	20.51 units on a scale Standard Deviation 22.446	21.84 units on a scale Standard Deviation 29.915
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 9	16.19 units on a scale Standard Deviation 18.737	20.51 units on a scale Standard Deviation 21.243
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 10	20.00 units on a scale Standard Deviation 25.820	24.64 units on a scale Standard Deviation 28.810
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 12	20.95 units on a scale Standard Deviation 26.918	19.70 units on a scale Standard Deviation 24.471
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 13	20.59 units on a scale Standard Deviation 24.638	23.81 units on a scale Standard Deviation 28.172
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 14	12.90 units on a scale Standard Deviation 22.240	22.81 units on a scale Standard Deviation 27.336
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 17	22.73 units on a scale Standard Deviation 25.996	15.56 units on a scale Standard Deviation 24.774
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 19	25.00 units on a scale Standard Deviation 20.719	16.67 units on a scale Standard Deviation 25.318
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 21	21.21 units on a scale Standard Deviation 22.473	13.89 units on a scale Standard Deviation 22.285
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 22	15.15 units on a scale Standard Deviation 22.918	24.24 units on a scale Standard Deviation 26.208
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 23	21.21 units on a scale Standard Deviation 26.968	23.33 units on a scale Standard Deviation 22.498
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 26	33.33 units on a scale Standard Deviation 27.217	28.57 units on a scale Standard Deviation 29.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 29	22.22 units on a scale Standard Deviation 27.217	33.33 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 31	22.22 units on a scale Standard Deviation 38.490	38.10 units on a scale Standard Deviation 29.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	44.44 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 40	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	55.56 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 41	—	55.56 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 43	—	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 7	19.05 units on a scale Standard Deviation 24.727	30.43 units on a scale Standard Deviation 37.488
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 9	13.33 units on a scale Standard Deviation 27.217	28.07 units on a scale Standard Deviation 31.940
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 10	17.33 units on a scale Standard Deviation 29.059	27.08 units on a scale Standard Deviation 32.702
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 17	20.00 units on a scale Standard Deviation 27.603	22.22 units on a scale Standard Deviation 25.950
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 21	23.81 units on a scale Standard Deviation 25.198	14.81 units on a scale Standard Deviation 24.216
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 27	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 28	33.33 units on a scale Standard Deviation 33.333	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 30	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 32	22.22 units on a scale Standard Deviation 38.490	20.00 units on a scale Standard Deviation 29.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 33	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	20.00 units on a scale Standard Deviation 29.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 34	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	33.33 units on a scale Standard Deviation 33.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 35	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	20.00 units on a scale Standard Deviation 29.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	25.00 units on a scale Standard Deviation 31.914
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	33.33 units on a scale Standard Deviation 33.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 40	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 41	—	16.67 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 3	5.45 units on a scale Standard Deviation 14.001	5.00 units on a scale Standard Deviation 14.222
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 4	4.67 units on a scale Standard Deviation 11.684	5.26 units on a scale Standard Deviation 12.318
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 24	10.00 units on a scale Standard Deviation 22.498	3.33 units on a scale Standard Deviation 10.541
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 1	21.67 units on a scale Standard Deviation 32.950	24.24 units on a scale Standard Deviation 24.234
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 8	13.51 units on a scale Standard Deviation 24.164	15.28 units on a scale Standard Deviation 24.035
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 38	—	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 7	18.77 units on a scale Standard Deviation 16.216	15.84 units on a scale Standard Deviation 17.207
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 8	20.48 units on a scale Standard Deviation 19.930	14.12 units on a scale Standard Deviation 17.870
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 9	18.23 units on a scale Standard Deviation 15.917	14.01 units on a scale Standard Deviation 17.558
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 20	15.15 units on a scale Standard Deviation 20.045	11.11 units on a scale Standard Deviation 17.568
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 21	20.20 units on a scale Standard Deviation 20.975	9.26 units on a scale Standard Deviation 12.385
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 18	24.31 units on a scale Standard Deviation 20.942	15.71 units on a scale Standard Deviation 12.433
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 20	25.45 units on a scale Standard Deviation 22.473	16.41 units on a scale Standard Deviation 15.303
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 27	34.44 units on a scale Standard Deviation 28.415	25.83 units on a scale Standard Deviation 20.912
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 28	28.57 units on a scale Standard Deviation 23.637	23.96 units on a scale Standard Deviation 20.967
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 31	24.44 units on a scale Standard Deviation 26.943	22.86 units on a scale Standard Deviation 19.572
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 38	—	27.92 units on a scale Standard Deviation 20.520
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 39	6.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	31.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	26.67 units on a scale Standard Deviation 17.638
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 41	—	35.56 units on a scale Standard Deviation 21.430
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 42	—	33.33 units on a scale Standard Deviation 18.856
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 1	9.47 units on a scale Standard Deviation 14.746	15.66 units on a scale Standard Deviation 20.378
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 2	9.94 units on a scale Standard Deviation 14.347	14.91 units on a scale Standard Deviation 16.407
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Gastrointestinal Symptoms: Cycle 43	—	20.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 5	12.29 units on a scale Standard Deviation 13.752	8.08 units on a scale Standard Deviation 12.507
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 7	12.82 units on a scale Standard Deviation 14.315	12.07 units on a scale Standard Deviation 16.538
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 1	12.57 units on a scale Standard Deviation 14.797	16.24 units on a scale Standard Deviation 19.038
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 4	17.53 units on a scale Standard Deviation 15.622	13.89 units on a scale Standard Deviation 16.074
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 5	15.06 units on a scale Standard Deviation 11.522	14.52 units on a scale Standard Deviation 15.361
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 13	10.46 units on a scale Standard Deviation 14.459	11.64 units on a scale Standard Deviation 15.899
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 15	13.33 units on a scale Standard Deviation 18.082	15.69 units on a scale Standard Deviation 18.864
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 16	10.70 units on a scale Standard Deviation 16.155	9.03 units on a scale Standard Deviation 11.631
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 11	16.83 units on a scale Standard Deviation 16.196	15.05 units on a scale Standard Deviation 21.453
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 12	16.01 units on a scale Standard Deviation 18.989	11.11 units on a scale Standard Deviation 13.494
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 22	14.14 units on a scale Standard Deviation 19.303	16.16 units on a scale Standard Deviation 21.294
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 13	15.45 units on a scale Standard Deviation 12.441	7.89 units on a scale Standard Deviation 8.942
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 14	13.60 units on a scale Standard Deviation 12.386	11.70 units on a scale Standard Deviation 13.968
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 24	22.22 units on a scale Standard Deviation 31.427	13.33 units on a scale Standard Deviation 14.628
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 15	15.48 units on a scale Standard Deviation 12.950	8.68 units on a scale Standard Deviation 12.664
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 17	14.81 units on a scale Standard Deviation 15.941	7.41 units on a scale Standard Deviation 8.572
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Endocrine Symptoms: Cycle 28	19.05 units on a scale Standard Deviation 29.197	12.50 units on a scale Standard Deviation 18.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 20	18.33 units on a scale Standard Deviation 17.382	9.72 units on a scale Standard Deviation 11.392
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 22	24.44 units on a scale Standard Deviation 22.253	12.63 units on a scale Standard Deviation 12.691
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 23	22.22 units on a scale Standard Deviation 23.570	13.89 units on a scale Standard Deviation 13.671
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 24	22.84 units on a scale Standard Deviation 24.602	11.67 units on a scale Standard Deviation 13.969
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 25	21.53 units on a scale Standard Deviation 21.504	15.28 units on a scale Standard Deviation 14.164
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 29	16.67 units on a scale Standard Deviation 4.536	15.87 units on a scale Standard Deviation 12.184
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 31	22.22 units on a scale Standard Deviation 11.111	20.63 units on a scale Standard Deviation 17.484
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 33	22.22 units on a scale Standard Deviation 11.111	20.37 units on a scale Standard Deviation 7.590
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 35	11.11 units on a scale Standard Deviation 15.713	17.59 units on a scale Standard Deviation 11.340
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 36	16.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	25.56 units on a scale Standard Deviation 7.454
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 37	16.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	26.39 units on a scale Standard Deviation 8.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 38	—	22.22 units on a scale Standard Deviation 11.111
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	29.63 units on a scale Standard Deviation 6.415
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	25.93 units on a scale Standard Deviation 6.415
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Treatment Related Symptoms: Cycle 41	—	24.07 units on a scale Standard Deviation 8.486
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 1	35.34 units on a scale Standard Deviation 22.907	31.06 units on a scale Standard Deviation 20.132
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 2	30.99 units on a scale Standard Deviation 21.490	29.81 units on a scale Standard Deviation 22.695
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 3	29.49 units on a scale Standard Deviation 20.534	30.00 units on a scale Standard Deviation 25.061
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 4	27.00 units on a scale Standard Deviation 19.441	26.17 units on a scale Standard Deviation 22.331
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 5	27.90 units on a scale Standard Deviation 19.087	24.24 units on a scale Standard Deviation 22.473
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 7	29.06 units on a scale Standard Deviation 20.171	27.20 units on a scale Standard Deviation 26.157
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 9	29.84 units on a scale Standard Deviation 27.715	23.08 units on a scale Standard Deviation 19.607
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 10	28.89 units on a scale Standard Deviation 22.579	24.64 units on a scale Standard Deviation 24.835
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 11	29.21 units on a scale Standard Deviation 21.573	24.07 units on a scale Standard Deviation 22.383
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 13	24.84 units on a scale Standard Deviation 23.380	23.81 units on a scale Standard Deviation 23.382
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 14	27.96 units on a scale Standard Deviation 20.056	25.73 units on a scale Standard Deviation 24.018
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 17	28.79 units on a scale Standard Deviation 21.320	23.70 units on a scale Standard Deviation 22.564
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 18	29.41 units on a scale Standard Deviation 26.040	26.98 units on a scale Standard Deviation 21.666
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 19	29.63 units on a scale Standard Deviation 25.219	28.57 units on a scale Standard Deviation 22.943
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 20	31.82 units on a scale Standard Deviation 28.119	29.06 units on a scale Standard Deviation 28.160
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 21	35.35 units on a scale Standard Deviation 30.151	24.07 units on a scale Standard Deviation 23.130
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 22	31.31 units on a scale Standard Deviation 28.029	27.27 units on a scale Standard Deviation 24.527
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 23	30.30 units on a scale Standard Deviation 28.149	26.67 units on a scale Standard Deviation 27.317
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 27	51.85 units on a scale Standard Deviation 28.689	33.33 units on a scale Standard Deviation 28.483
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 30	35.56 units on a scale Standard Deviation 26.527	30.16 units on a scale Standard Deviation 29.893
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 31	44.44 units on a scale Standard Deviation 22.222	30.16 units on a scale Standard Deviation 29.197
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 32	33.33 units on a scale Standard Deviation 11.111	31.48 units on a scale Standard Deviation 30.965
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 33	40.74 units on a scale Standard Deviation 23.130	40.74 units on a scale Standard Deviation 31.164
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 34	44.44 units on a scale Standard Deviation 22.222	35.19 units on a scale Standard Deviation 29.327
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 37	22.22 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	30.56 units on a scale Standard Deviation 39.933
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 38	—	41.67 units on a scale Standard Deviation 41.944
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 40	11.11 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	42.59 units on a scale Standard Deviation 36.991
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 41	—	44.44 units on a scale Standard Deviation 40.062
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Social Functioning: Cycle 43	—	11.11 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 1	49.27 units on a scale Standard Deviation 26.381	42.89 units on a scale Standard Deviation 23.108
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 2	38.01 units on a scale Standard Deviation 24.550	36.04 units on a scale Standard Deviation 24.942
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 4	31.89 units on a scale Standard Deviation 22.075	33.19 units on a scale Standard Deviation 23.904
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 5	37.12 units on a scale Standard Deviation 25.619	30.64 units on a scale Standard Deviation 22.742
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 7	39.32 units on a scale Standard Deviation 24.825	32.18 units on a scale Standard Deviation 26.618
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 8	38.29 units on a scale Standard Deviation 25.653	32.00 units on a scale Standard Deviation 22.753
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 12	35.56 units on a scale Standard Deviation 28.621	29.29 units on a scale Standard Deviation 25.325
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 13	34.64 units on a scale Standard Deviation 27.046	30.16 units on a scale Standard Deviation 24.881
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 14	32.97 units on a scale Standard Deviation 22.312	31.87 units on a scale Standard Deviation 22.055
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 15	34.44 units on a scale Standard Deviation 25.160	33.66 units on a scale Standard Deviation 27.250
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 16	34.16 units on a scale Standard Deviation 25.022	37.85 units on a scale Standard Deviation 23.589
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 21	39.90 units on a scale Standard Deviation 30.512	27.78 units on a scale Standard Deviation 30.887
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 23	36.36 units on a scale Standard Deviation 35.168	26.11 units on a scale Standard Deviation 29.403
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 24	41.11 units on a scale Standard Deviation 32.309	27.78 units on a scale Standard Deviation 28.328
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 25	38.33 units on a scale Standard Deviation 32.547	38.89 units on a scale Standard Deviation 31.983
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 26	42.86 units on a scale Standard Deviation 33.597	31.75 units on a scale Standard Deviation 33.597
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 28	50.79 units on a scale Standard Deviation 38.946	40.28 units on a scale Standard Deviation 39.368
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 29	37.96 units on a scale Standard Deviation 35.210	38.10 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 30	35.56 units on a scale Standard Deviation 38.809	34.92 units on a scale Standard Deviation 29.696
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 34	55.56 units on a scale Standard Deviation 40.062	35.19 units on a scale Standard Deviation 36.796
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	22.22 units on a scale Standard Deviation 31.427
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 38	—	33.33 units on a scale Standard Deviation 45.361
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	44.44 units on a scale Standard Deviation 50.918
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	37.04 units on a scale Standard Deviation 35.717
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 41	—	44.44 units on a scale Standard Deviation 50.918
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 42	—	50.00 units on a scale Standard Deviation 54.997
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Disease Related Worries: EOT	50.84 units on a scale Standard Deviation 27.079	41.38 units on a scale Standard Deviation 30.123
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 1	13.56 units on a scale Standard Deviation 20.640	13.64 units on a scale Standard Deviation 20.734
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 2	20.47 units on a scale Standard Deviation 24.197	17.89 units on a scale Standard Deviation 23.685
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 3	16.36 units on a scale Standard Deviation 19.108	23.33 units on a scale Standard Deviation 24.108
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 4	16.00 units on a scale Standard Deviation 20.471	21.93 units on a scale Standard Deviation 26.024
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 5	17.02 units on a scale Standard Deviation 18.221	22.22 units on a scale Standard Deviation 27.217
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 8	20.72 units on a scale Standard Deviation 22.705	20.00 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 11	21.90 units on a scale Standard Deviation 25.492	22.22 units on a scale Standard Deviation 25.380
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 15	11.49 units on a scale Standard Deviation 18.422	25.49 units on a scale Standard Deviation 32.338
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 16	19.75 units on a scale Standard Deviation 24.909	16.67 units on a scale Standard Deviation 24.343
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 18	15.69 units on a scale Standard Deviation 20.809	14.29 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 20	27.27 units on a scale Standard Deviation 25.025	12.82 units on a scale Standard Deviation 21.681
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 24	20.00 units on a scale Standard Deviation 23.307	30.00 units on a scale Standard Deviation 29.187
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 25	23.33 units on a scale Standard Deviation 27.442	33.33 units on a scale Standard Deviation 30.861
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 27	50.00 units on a scale Standard Deviation 18.257	29.17 units on a scale Standard Deviation 27.817
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 28	38.10 units on a scale Standard Deviation 23.002	33.33 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 30	26.67 units on a scale Standard Deviation 27.889	28.57 units on a scale Standard Deviation 35.635
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 32	22.22 units on a scale Standard Deviation 38.490	38.89 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 33	33.33 units on a scale Standard Deviation 33.333	33.33 units on a scale Standard Deviation 29.814
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 34	11.11 units on a scale Standard Deviation 19.245	44.44 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 35	33.33 units on a scale Standard Deviation 47.140	38.89 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	53.33 units on a scale Standard Deviation 18.257
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	50.00 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 38	—	58.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: Cycle 42	—	50.00 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Muscle/Bone Pain Symptom: EOT	25.25 units on a scale Standard Deviation 27.677	26.44 units on a scale Standard Deviation 30.052
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 1	22.55 units on a scale Standard Deviation 31.485	34.48 units on a scale Standard Deviation 35.054
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 2	17.83 units on a scale Standard Deviation 25.561	30.00 units on a scale Standard Deviation 30.763
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 3	17.95 units on a scale Standard Deviation 25.185	36.78 units on a scale Standard Deviation 32.544
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 4	18.63 units on a scale Standard Deviation 24.878	22.22 units on a scale Standard Deviation 30.662
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 5	18.75 units on a scale Standard Deviation 25.312	28.40 units on a scale Standard Deviation 35.450
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 6	14.44 units on a scale Standard Deviation 20.869	31.88 units on a scale Standard Deviation 35.503
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 8	23.08 units on a scale Standard Deviation 27.919	27.08 units on a scale Standard Deviation 27.806
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 11	16.00 units on a scale Standard Deviation 25.676	20.83 units on a scale Standard Deviation 26.874
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 12	20.51 units on a scale Standard Deviation 29.929	19.05 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 13	16.67 units on a scale Standard Deviation 26.006	22.22 units on a scale Standard Deviation 32.530
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 14	20.00 units on a scale Standard Deviation 27.217	26.19 units on a scale Standard Deviation 26.726
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 15	17.46 units on a scale Standard Deviation 27.119	19.44 units on a scale Standard Deviation 26.432
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 16	22.81 units on a scale Standard Deviation 33.431	25.64 units on a scale Standard Deviation 27.735
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 18	22.22 units on a scale Standard Deviation 21.711	18.18 units on a scale Standard Deviation 27.340
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 19	19.05 units on a scale Standard Deviation 26.227	20.00 units on a scale Standard Deviation 28.109
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 20	25.00 units on a scale Standard Deviation 29.547	13.33 units on a scale Standard Deviation 23.307
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 22	33.33 units on a scale Standard Deviation 30.861	14.81 units on a scale Standard Deviation 24.216
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 23	23.81 units on a scale Standard Deviation 31.706	20.83 units on a scale Standard Deviation 24.801
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 24	26.67 units on a scale Standard Deviation 27.889	16.67 units on a scale Standard Deviation 25.198
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 25	26.67 units on a scale Standard Deviation 36.515	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 26	25.00 units on a scale Standard Deviation 31.914	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 29	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 31	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 27.889
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 38	—	33.33 units on a scale Standard Deviation 33.333
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 39	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	16.67 units on a scale Standard Deviation 23.570
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 42	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Sexual Function: EOT	25.76 units on a scale Standard Deviation 27.084	49.12 units on a scale Standard Deviation 37.463
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 1	8.74 units on a scale Standard Deviation 21.860	6.82 units on a scale Standard Deviation 15.384
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 2	5.85 units on a scale Standard Deviation 12.791	5.69 units on a scale Standard Deviation 14.724
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 5	3.55 units on a scale Standard Deviation 10.389	7.07 units on a scale Standard Deviation 18.177
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 6	4.65 units on a scale Standard Deviation 11.687	5.38 units on a scale Standard Deviation 15.146
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 7	6.84 units on a scale Standard Deviation 13.636	9.20 units on a scale Standard Deviation 23.395
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 8	8.11 units on a scale Standard Deviation 16.491	5.33 units on a scale Standard Deviation 15.753
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 9	5.71 units on a scale Standard Deviation 12.746	3.85 units on a scale Standard Deviation 10.860
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 10	8.57 units on a scale Standard Deviation 16.848	7.25 units on a scale Standard Deviation 17.281
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 11	7.62 units on a scale Standard Deviation 18.232	5.56 units on a scale Standard Deviation 16.051
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 12	10.48 units on a scale Standard Deviation 22.537	1.52 units on a scale Standard Deviation 7.107
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 13	3.92 units on a scale Standard Deviation 10.901	4.76 units on a scale Standard Deviation 11.952
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 14	6.45 units on a scale Standard Deviation 13.387	3.51 units on a scale Standard Deviation 10.510
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 15	4.44 units on a scale Standard Deviation 11.525	7.84 units on a scale Standard Deviation 18.743
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 16	2.47 units on a scale Standard Deviation 8.896	8.33 units on a scale Standard Deviation 14.907
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 17	4.55 units on a scale Standard Deviation 11.708	2.22 units on a scale Standard Deviation 8.607
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 18	7.84 units on a scale Standard Deviation 14.575	7.14 units on a scale Standard Deviation 19.298
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 19	0.00 units on a scale Standard Deviation 0.000	2.38 units on a scale Standard Deviation 8.909
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 20	3.03 units on a scale Standard Deviation 10.050	2.56 units on a scale Standard Deviation 9.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 21	6.06 units on a scale Standard Deviation 13.484	2.78 units on a scale Standard Deviation 9.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 22	6.06 units on a scale Standard Deviation 13.484	3.03 units on a scale Standard Deviation 10.050
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 23	9.09 units on a scale Standard Deviation 21.556	3.33 units on a scale Standard Deviation 10.541
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 25	6.67 units on a scale Standard Deviation 14.055	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 26	11.11 units on a scale Standard Deviation 17.213	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 27	0.00 units on a scale Standard Deviation 0.000	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 28	9.52 units on a scale Standard Deviation 16.265	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 29	5.56 units on a scale Standard Deviation 13.608	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 30	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 31	0.00 units on a scale Standard Deviation 0.000	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 32	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 33	11.11 units on a scale Standard Deviation 19.245	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 34	11.11 units on a scale Standard Deviation 19.245	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 35	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 38	—	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 40	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 41	—	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Information/Communication: EOT	10.10 units on a scale Standard Deviation 19.516	5.75 units on a scale Standard Deviation 20.057
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 2	12.87 units on a scale Standard Deviation 19.674	15.45 units on a scale Standard Deviation 25.925
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 3	10.90 units on a scale Standard Deviation 21.614	19.17 units on a scale Standard Deviation 31.020
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 4	10.88 units on a scale Standard Deviation 17.197	16.67 units on a scale Standard Deviation 24.199
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 5	8.70 units on a scale Standard Deviation 17.826	15.15 units on a scale Standard Deviation 25.126
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 6	11.90 units on a scale Standard Deviation 21.866	21.11 units on a scale Standard Deviation 29.664
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 7	14.91 units on a scale Standard Deviation 25.347	21.43 units on a scale Standard Deviation 31.706
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 9	14.29 units on a scale Standard Deviation 28.337	14.67 units on a scale Standard Deviation 23.727
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 10	13.73 units on a scale Standard Deviation 24.779	18.84 units on a scale Standard Deviation 26.258
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 11	12.38 units on a scale Standard Deviation 19.944	15.28 units on a scale Standard Deviation 24.035
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 12	10.48 units on a scale Standard Deviation 21.038	9.09 units on a scale Standard Deviation 23.417
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 13	7.84 units on a scale Standard Deviation 20.199	7.94 units on a scale Standard Deviation 17.965
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 14	12.90 units on a scale Standard Deviation 23.847	7.02 units on a scale Standard Deviation 13.962
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 15	9.20 units on a scale Standard Deviation 21.633	9.80 units on a scale Standard Deviation 19.596
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 16	16.05 units on a scale Standard Deviation 28.300	10.42 units on a scale Standard Deviation 23.472
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 17	12.12 units on a scale Standard Deviation 26.318	8.89 units on a scale Standard Deviation 15.258
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 18	15.69 units on a scale Standard Deviation 31.441	7.14 units on a scale Standard Deviation 14.194
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 19	11.11 units on a scale Standard Deviation 25.950	2.38 units on a scale Standard Deviation 8.909
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 20	9.09 units on a scale Standard Deviation 30.151	8.33 units on a scale Standard Deviation 15.076
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 21	9.09 units on a scale Standard Deviation 30.151	2.78 units on a scale Standard Deviation 9.623
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 22	15.15 units on a scale Standard Deviation 31.140	6.06 units on a scale Standard Deviation 13.484
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 23	9.09 units on a scale Standard Deviation 21.556	6.67 units on a scale Standard Deviation 14.055
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 24	16.67 units on a scale Standard Deviation 36.004	3.33 units on a scale Standard Deviation 10.541
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 25	16.67 units on a scale Standard Deviation 36.004	8.33 units on a scale Standard Deviation 15.430
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 26	23.81 units on a scale Standard Deviation 41.786	4.76 units on a scale Standard Deviation 12.599
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 27	22.22 units on a scale Standard Deviation 40.369	4.17 units on a scale Standard Deviation 11.785
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 28	22.22 units on a scale Standard Deviation 40.369	12.50 units on a scale Standard Deviation 17.252
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 29	11.11 units on a scale Standard Deviation 27.217	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 30	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 31	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 32	0.00 units on a scale Standard Deviation 0.000	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 33	0.00 units on a scale Standard Deviation 0.000	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 34	22.22 units on a scale Standard Deviation 38.490	5.56 units on a scale Standard Deviation 13.608
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 35	16.67 units on a scale Standard Deviation 23.570	11.11 units on a scale Standard Deviation 17.213
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 36	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 37	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	8.33 units on a scale Standard Deviation 16.667
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 39	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.	22.22 units on a scale Standard Deviation 38.490
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 41	—	11.11 units on a scale Standard Deviation 19.245
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 42	—	0.00 units on a scale Standard Deviation 0.000
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: Cycle 43	—	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only 1 participant was evaluable.
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21) Body Image: EOT	23.23 units on a scale Standard Deviation 32.792	18.39 units on a scale Standard Deviation 31.605

SECONDARY outcome

Timeframe: Pre-dose on Day 1 and 15 of Cycle 1, Day 1 of Cycle 2, 3 and every 2 cycles thereafter (Cycle 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43), End of Treatment (up to maximum duration of 1226 days)

Population: sKIT analysis set: enrolled participants who received at least 1 dose of study drug, had at least 1 biomarker parameter from corresponding assay sample with both baseline and post-treatment assessment. Here, "0 participants" in "number analyzed" field=none of the participants were evaluable in given group at this time point, hence data not reported

Outcome measures

SECONDARY outcome

Timeframe: Pre-dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5

Population: Pharmacokinetic (PK) population included all participants who received at least 1 dose of study medication, had baseline and at least 1 post-baseline value for each parameters.

Ctrough is the minimum observed plasma concentration of drug. SU012662 is the metabolite of sunitinib.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle5/Day1	35.57 nanogram per milliliter (ng/mL) Standard Deviation 15.221	33.60 nanogram per milliliter (ng/mL) Standard Deviation 15.010
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 SU012662: Cycle1/Day15	18.03 nanogram per milliliter (ng/mL) Standard Deviation 11.169	14.26 nanogram per milliliter (ng/mL) Standard Deviation 9.264
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 SU012662: Cycle2/Day1	15.94 nanogram per milliliter (ng/mL) Standard Deviation 9.059	12.53 nanogram per milliliter (ng/mL) Standard Deviation 8.000
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 SU012662: Cycle3/Day1	15.85 nanogram per milliliter (ng/mL) Standard Deviation 9.444	13.64 nanogram per milliliter (ng/mL) Standard Deviation 6.983
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 SU012662: Cycle5/Day1	12.78 nanogram per milliliter (ng/mL) Standard Deviation 6.375	12.61 nanogram per milliliter (ng/mL) Standard Deviation 6.735
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle1/Day15	52.78 nanogram per milliliter (ng/mL) Standard Deviation 27.361	41.93 nanogram per milliliter (ng/mL) Standard Deviation 21.707
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle2/Day1	42.68 nanogram per milliliter (ng/mL) Standard Deviation 20.320	38.38 nanogram per milliliter (ng/mL) Standard Deviation 22.765
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle3/Day1	41.79 nanogram per milliliter (ng/mL) Standard Deviation 21.517	38.49 nanogram per milliliter (ng/mL) Standard Deviation 18.750

SECONDARY outcome

Timeframe: Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5

Population: PK population included all participants who received at least 1 dose of study medication, had baseline and at least 1 post-baseline value for each parameters.

Dose-corrected plasma trough concentration is calculated as: trough plasma concentration\*(intended dose divided by actual dose). Intended dose was defined as the starting dose in the study and actual dose was defined as the last dose which the participant had received. SU012662 is the metabolite of sunitinib.

Outcome measures

Outcome measures
Measure	Sunitinib: Treatment Naive Cohort n=61 Participants Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive participants.	Sunitinib: Later-Line Cohort n=45 Participants Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 64 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/later-line participants (participants who developed progressive disease on or after prior systemic therapy).
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle1/Day15	52.66 ng/mL Standard Deviation 27.136	43.38 ng/mL Standard Deviation 21.520
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle2/Day1	42.89 ng/mL Standard Deviation 20.607	39.52 ng/mL Standard Deviation 19.833
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle3/Day1	44.99 ng/mL Standard Deviation 23.031	38.56 ng/mL Standard Deviation 18.375
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 Sunitinib: Cycle5/Day1	42.49 ng/mL Standard Deviation 16.769	33.27 ng/mL Standard Deviation 16.733
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 SU012662: Cycle1/Day15	18.14 ng/mL Standard Deviation 11.059	14.79 ng/mL Standard Deviation 9.436
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 SU012662: Cycle2/Day1	16.01 ng/mL Standard Deviation 9.132	13.09 ng/mL Standard Deviation 7.684
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 SU012662: Cycle3/Day1	17.37 ng/mL Standard Deviation 10.233	14.22 ng/mL Standard Deviation 7.085
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662 SU012662: Cycle5/Day1	15.35 ng/mL Standard Deviation 6.882	12.53 ng/mL Standard Deviation 6.914

SECONDARY outcome

Timeframe: Pre-dose (0 hour) and at multiple time points (up to 24 hours) post dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)

Population: Due to insufficient data, there was substantial uncertainty associated with the parameter estimates; therefore, the population PK/PD analyses was not completed. Instead, the exposure response analyses with respect to different safety and efficacy endpoints were carried out and reported.

Area under the plasma concentration-time profile from time zero (pre-dose) to 24 hours post-dose. SU012662 is the metabolite of sunitinib.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)

Clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)

Concentration of sunitinib in plasma at which 50 percent of the maximum effect was observed.